1	Does early childhood BCG vaccination improve survival into adulthood in a
2	population with a low tuberculosis prevalence? Quasi-experimental evidence
3	on non-specific effects from 39 Swedish birth cohorts
4	
5	Michaela Theilmann <sup>1,6</sup>
6	Pascal Geldsetzer <sup>2,3</sup>
7	Till Bärnighausen <sup>1,4,5</sup>
8	Nikkil Sudharsanan <sup>1,6</sup> *
9	
10	
11	<sup>1</sup> Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital,
12	Heidelberg University, 69120 Heidelberg, Germany
13	<sup>2</sup> Division of Primary Care and Population Health, Stanford University, Stanford, CA 94305,
14	United States
15	<sup>3</sup> Chan Zuckerberg Biohub, San Francisco, CA 94158, United States
16	<sup>4</sup> Harvard Center for Population and Development Studies, Cambridge, MA 02138, United
17	States
18	<sup>5</sup> Africa Health Research Institute, 3935 KwaZulu-Natal, South Africa
19	<sup>6</sup> Professorship of Behavioral Science for Disease Prevention and Health Care and Institute
20	for Advanced Study, Technical University of Munich, 80992 Munich, Germany
21	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 22 Abstract

The Bacillus Calmette–Guérin (BCG) vaccine for tuberculosis (TB) is widely used globally. 23 Many high-income countries discontinued nationwide vaccination policies as the TB 24 prevalence decreased. However, there is continued interest in whether the general childhood 25 immunity boost conferred by the BCG vaccination impacts adult health and mortality in low-26 TB contexts (known as non-specific effects) and whether BCG vaccination should be continued 27 28 as a population policy. While recent studies found evidence of an association between BCG vaccination and later-life survival, it is unclear whether these associations are causal or driven 29 30 by unobserved characteristics of those who chose to voluntarily vaccinate. We use the abrupt discontinuation of mandatory BCG vaccination in Sweden in 1975 as a natural experiment to 31 estimate the causal non-specific effect of the BCG vaccine on long-term cohort survival. 32 33 Applying two complementary study designs, we find no evidence that survival to age 30 was 34 affected by the discontinuation of childhood BCG vaccination. The results are consistent in the male and female subpopulations and are robust to several sensitivity and falsification tests. 35 Overall, despite interest and prior correlational studies suggesting large non-specific effects, 36 37 we do not find any population-level evidence for a non-specific effect of the BCG vaccine discontinuation on long-term survival in Sweden. 38

39

40 Keywords: Vaccines, non-specific effects, life-course, survival, causal inference

- 41
- 42
- 43

# 44 Introduction

Tuberculosis (TB) was a major cause of mortality in Europe in the 18<sup>th</sup> century and is estimated 45 to have caused 1,000 deaths per 100,000 people (Murray, 2001). The Bacillus Calmette–Guérin 46 (BCG) vaccine was developed in the 1910s to address the global TB burden and was 47 administered to the first child in 1921 (Dara et al., 2014). BCG vaccination was then scaled up 48 49 widely in the 1940s across Europe. It became the main government strategy for containing TB 50 and many high-income countries (HIC) introduced national policies making BCG vaccination compulsory for children (Zwerling et al., 2011). As the incidence of TB declined to negligible 51 52 levels, several HICs discontinued compulsory vaccinations. However, there has been continued 53 and significant scientific interest in the non-specific effects of the BCG vaccine and whether it increases long-term survival beyond its effects on TB. 54

The proposed mechanism behind non-specific BCG effects is that early BCG 55 vaccination improves general childhood immunity, which may confer a lasting health impact 56 as individuals age (Cirovic et al., 2020; Dockrell & Smith, 2017). This hypothesis is consistent 57 with life course theories in demography in population health that link early life conditions and 58 events with later life morbidity and mortality (Case & Paxson, 2010; Cutler & Miller, 2005; 59 60 Elo & Preston, 1992; Helgertz & Bengtsson, 2019; Masters, 2018; McEnry & Palloni, 2010; 61 Palloni & Souza, 2013; van den Berg, Doblhammer-Reiter, & Christensen, 2011; Wen & Gu, 2011; Zhao, Hessel, Simon Thomas, & Beckfield, 2021). Despite the growing scientific interest 62 63 over the past two decades, especially among laboratory scientists studying cellular-level immune response to the vaccine, it is still inconclusive whether the early childhood 64 improvement in immune response created by the BCG vaccine has a causal impact on health 65 in later life (Dockrell & Smith, 2017; Goodridge et al., 2016). 66

67 There exists a small body of literature analysing the relationship between the BCG
68 vaccine and morbidity and mortality among adults (Giamarellos-Bourboulis et al., 2020;

69 Kölmel et al., 2005; Lankes, Fought, Evens, Weisenburger, & Chiu, 2009; Pfahlberg et al., 70 2002; Rieckmann; Rieckmann, Villumsen, Jensen, et al., 2017; Rieckmann, Villumsen, Sørup, et al., 2017; Villumsen et al., 2009; Villumsen et al., 2013; Wardhana, Sultana, Mandang, & 71 72 Jim, 2011). Indeed, a recent study suggested that children vaccinated with the BCG vaccine in Denmark had an 42% lower hazard of mortality in adulthood (Rieckmann, Villumsen, Sørup, 73 et al., 2017). If this association was in fact evidence of a causal relationship, these results would 74 75 have significant population policy implications and would suggest that re-introducing BCG vaccination in national vaccination plans, even in the absence of TB, may be a cost-effective 76 77 and easy-to-implement way of improving long-term survival. However, these studies are either 78 based on small non-representative samples, limited to specific health outcomes rather than an 79 overall measure like all-cause mortality, and most fundamentally are based on study designs 80 that suffer from confounding. Thus, it is unclear whether the association between BCG and 81 later-life survival is due to the causal effect of improved childhood immunity from vaccination or reflects the unobserved characteristics of the families and children that opted for the vaccine. 82 83 To our knowledge, there is no causal evidence on the non-specific effects of the vaccine on long-term survival at the population level. 84

85 In this paper, we address these three key limitations. First, rather than rely on small or potentially non-representative samples, we use population data on births and deaths in Sweden 86 87 for birth cohorts born between 1950 and 1988. Second, rather than focus on specific health 88 conditions, we examine the effects of BCG vaccination on cohort survival to age 30 based on all-cause mortality. Lastly, we employ two causal inference study designs – the Regression 89 90 Discontinuity Design (RDD) and the multi-period Difference in Differences (DiD) model – to 91 address the potential issues of confounding found in prior studies. In contrast to prior studies, 92 we do not find that the BCG vaccine had non-specific effects on survival to age 30 in Sweden. 93 This result is consistent across analysis approaches and robust to several sensitivity analyses

and alternate specifications. While BCG vaccination in the absence of TB might still be
important for certain specific subpopulations, our results do not provide evidence in support of
broad population policies to re-introduce BCG vaccination in HICs with a low burden of TB.

\_

# 98 Background

## 99 Epidemiology of Tuberculosis

TB is an infectious disease caused by the mycobacterium tuberculosis bacterium that mostly affects the lungs but can also spread to other organs or the bones (Raviglione Mario C., 2018). TB is highly fatal if untreated but can be treated with a six-month antibiotic drug regimen. It is transmitted through the air (e.g. from talking or coughing) and is mainly observed among adults, males, and those that are immunocompromised (e.g. living with HIV), living with diabetes, undernourished, and those that use alcohol or tobacco (Lönnroth, Jaramillo, Williams, Dye, & Raviglione, 2009).

107 The mycobacterium tuberculosis has been around for thousands of years but tuberculosis prevalence increased to an epidemic level only in the 18<sup>th</sup> century, reaching an 108 estimated death rate of 1,000 per 100,000 inhabitants in 1800 (Barberis, Bragazzi, Galluzzo, & 109 Martini, 2017; Chisholm, Trauer, Curnoe, & Tanaka, 2016; Hershkovitz et al., 2015; Murray, 110 111 2001). This dramatic increase in TB mortality is thought to be related to increasing urbanization 112 and the close agglomeration of individuals in cities as well as poor living standards (Lönnroth et al., 2009). In the 19th century, the TB prevalence declined in high-income countries (Wilson, 113 1990) While TB remains the second highest cause of death from infectious diseases globally, 114 115 after COVID-19, in 2020, this burden is concentrated in low and middle-income countries, with high-income countries only accounting for 2% of all recorded TB cases (World Health 116 117 Organization, 2021).

#### 119 Development and Introduction of the BCG Vaccine in Europe

The BCG vaccine is a live vaccine and was introduced in the 1920s (Dara et al., 2014). Since 120 then it has become one of the most widely used vaccines globally (Dara et al., 2014; Muhoza 121 122 et al., 2021). Several strains of the BCG vaccine emerged from the original strain isolated by Albert Calmette and Camille Guérin in 1908 (Dara et al., 2014). There is conflicting evidence 123 on the effectiveness of the vaccine and to date, it is poorly understood how the BCG vaccine 124 125 affects the immune system and why there is such a wide variation in the body's immunological response (Dockrell & Smith, 2017). While evidence is mixed, it is generally believed that the 126 127 BCG vaccine only protects against the development of active TB but not infection itself, and that the vaccine has the greatest benefits when administered after birth rather than to 128 129 adolescents or adults (World Health Organization; Abubakar et al., 2013). The BCG vaccine 130 is safe for healthy children but poses a threat to immunodeficient children, who can develop a disseminated BCG infection (World Health Organization, 2018). This fact is important for 131 deciding which children should be given the BCG vaccination, a point which we will return to 132 later on when discussing potential issues of confounding in prior research. 133

In Europe, the BCG vaccine was widely adopted in the 1940s (Dara et al., 2014). In the 134 large majority of countries it was administered right after birth (Zwerling et al., 2011). While 135 some countries, such as Sweden and Norway, made the BCG vaccination compulsory, other 136 137 countries adopted policies that targeted high-risk groups only, such as healthcare workers or 138 children of parents born in high-incidence countries. In the decades after the introduction of the BCG vaccine, the TB incidence continued to decrease dramatically in Western Europe and 139 other high-income countries (Daniel, 2006). This decline lead most of the countries where 140 141 vaccination was compulsory to discontinue their policies (Böttiger, Romanus, Verdier, & 142 Boman, 1982). In Sweden, for example, TB mortality decreased from around 22 per 100,000 in 1950 to less than 4 per 100,000 in 1975 (Committee on Government Operations, United 143

States Congress Senate; Sakari Härö, 1994). In Norway, mortality attributable to TB was 29 per 100,000 people in 1950 and decreased to 2 per 100,000 in 1975 (Central Bureau of Statistics Norway, 1961).<sup>1</sup> Importantly, it remains unclear how much the BCG vaccine contributed to the decline in TB prevalence, or whether this decline was mainly due to improved living standards and nutrition (Wilson, 1990).

In Sweden, the country we study here, compulsory vaccination of neonates was 149 150 introduced in 1940 and then reversed in April 1975 because of the persistently low TB prevalence (The Public Health Agency of Sweden, 2020; Bergström, Mäkinen, & Romanus, 151 152 2001; Zwerling et al., 2011). Thus, children born in 1976 were the first birth cohort in which no newborn received the routine BCG vaccine. This shift was abrupt: vaccine coverage 153 dropped from 95% to 2% in the years following its discontinuation (Romanus, 2006). Coverage 154 155 then gradually increased to 13.1% in the cohort born in 1989 and covered at-risk groups such as children born to parents from high TB incidence countries (Bergström et al., 2001). In 156 Norway, BCG vaccinations became compulsory in 1947 for students leaving elementary 157 school, usually at age 13 (Waaler, Galtung, & Mordal, 1971). Mass vaccination campaigns 158 started in 1947 (Tverdak & Funnemark, 1988). However, unlike Sweden, mandatory 159 vaccination in Norway remained until 2005, when the policy changed to a voluntary scheme, 160 161 and again in 2009, when the vaccination recommendation was limited to at risk groups only 162 (Norwegian Institute of Public Health, 2008; Norwegian Institute of Public Health, 2016). BCG 163 vaccine coverage in Norway increased from 88.6% among adolescents aged 13 in 1959 to 92.2% in 1973 and was above 97% since 1975 (Norwegian Institute of Public Health; Tverdak 164 & Funnemark, 1988). 165

<sup>&</sup>lt;sup>1</sup> To our knowledge, no data on the TB related mortality rate were available. Thus, we used the absolute numbers of TB cases and divided them by the population size in the respective year (Statistics Norway; The World Bank (2022))

### 167 Non-Specific Effects of the BCG Vaccine

Non-specific effects are health effects of a vaccine that are unrelated to the targeted disease. 168 The first non-specific effects were reported on the vaccinia vaccine against smallpox, which 169 170 also seemed to protect against measles and other infectious diseases (Mayr, 2004). These 171 findings led to the assumption that other live vaccines, such as the BCG vaccine, might have positive non-specific effects (Higgins et al., 2016). It is not entirely clear through which 172 173 channels the BCG vaccine could provide protection against other diseases. There is evidence that the BCG vaccine causes an adaption of the innate, or unspecific, immunity, which is the 174 175 fraction of the immune system humans have from birth on and is, thus, not induced in response to specific diseases through infection or vaccination (Roberts, Alberts, Bruce, Johnson, 176 Alexander, Lewis, Raff, & Walter, 2015). This trained immunity, i.e. the change in the innate 177 178 immunity after BCG vaccination, is one of the potential channels for the BCG vaccine related 179 non-specific effects (Moorlag, Arts, van Crevel, & Netea, 2019). This physiological mechanism is consistent with a broader body of evidence from demography and population 180 181 health which finds a robust link between early childhood health and changes to the immune 182 system and later life (Bonanni, 1999; Drummond, Chevat, & Lothgren, 2007; Karafillakis, Hassounah, & Atchison, 2015; Mercer, 1985; Michiels, Govaerts, Remmen, Vermeire, & 183 Coenen, 2011). Today, the BCG vaccine is widely applied as a treatment for bladder cancer 184 185 and research on its effectiveness in the treatment of other cancers is ongoing (Lamm & Morales, 186 2021).

187

## 188 Existing evidence of non-specific BCG effects

There is a small number of studies, most of them observational, estimating non-specific effects
of the BCG vaccine on child survival (Biering-Sørensen et al., 2018; Breiman et al., 2004;
Castro, Pardo-Seco, & Martinón-Torres, 2015; Elguero, Simondon, Vaugelade, Marra, &

192 Simondon, 2005; Garly et al., 2003; Lehmann, Vail, Firth, Klerk, & Alpers, 2005; Nankabirwa, Tumwine, Mugaba, Tylleskär, & Sommerfelt, 2015; Roth et al., 2005; Schaltz-Buchholzer, 193 Aaby, et al., 2021; Schaltz-Buchholzer, Kjær Sørensen, Benn, & Aaby, 2021; Steenhuis et al., 194 195 2008; Thysen et al., 2020; Vaugelade, Pinchinat, Guiella, Elguero, & Simondon, 2004). The majority of these studies was conducted in low- and middle-income countries and suggest a 196 positive association between BCG vaccine and child survival. Evidence on the vaccine's non-197 198 specific effect on adult morbidity and mortality is also limited (Giamarellos-Bourboulis et al., 2020; Kölmel et al., 2005; Lankes et al., 2009; Pfahlberg et al., 2002; Rieckmann; Rieckmann, 199 200 Villumsen, Jensen, et al., 2017; Rieckmann, Villumsen, Sørup, et al., 2017; Villumsen et al., 2009; Villumsen et al., 2013; Wardhana et al., 2011). All studies but one are based on small 201 non-representative samples or are limited to specific health outcomes (Rieckmann, Villumsen, 202 203 Sørup, et al., 2017). Most importantly, all studies except for one clinical trial do not sufficiently 204 account for potential confounding and can thus only estimate associations but not establish causal relationships (Giamarellos-Bourboulis et al., 2020). 205

For example, Pfahlberg et al. (2002) study the relationship between BCG vaccination 206 and malignant melanoma among 1,230 individuals from eleven health centers in seven 207 European countries between 1994 and 1997. Using a case-control design, the authors compare 208 those that did and did not receive the BCG vaccine and conclude that the BCG vaccine might 209 210 reduce the risk of malignant melanoma. In contrast, Riekmann et al. (2019) link data on 5,090 211 adults from the Copenhagen School Health Records to the Danish Cancer Registry and find no association between BCG vaccination and malignant melanoma. Focusing on lymphoma and 212 leukaemia, Villumsen et al. (2009) also use data from the Copenhagen School Health Records 213 214 and find that individuals who had received the BCG vaccine had half the risk of developing lymphoma compared to those who had not. However, there was no difference in the risk of 215 developing leukaemia. 216

Two observational studies analyse the association between BCG vaccination and adult 217 survival. Kölmel et al. (2005) analysed the association of the vaccinia and BCG vaccines with 218 survival among individuals with malignant melanoma in six European countries and Israel. The 219 authors compared participants with the vaccine to those without and found no evidence of an 220 association between the BCG vaccine and survival among individuals with malignant 221 222 melanoma. The only study analysing the relationship between the BCG vaccination and long-223 term survival used the Copenhagen School Health Records Register used as part of the prior mentioned papers. Rieckmann et al. (2017) linked these data to the Civil Registration System 224 225 and the Danish Register of Causes of Death databases, focusing on death by natural causes (excluding tuberculosis or smallpox). Comparing those that did receive the BCG vaccine to 226 those that did not, they found that vaccinated individuals had approximately half the risk of 227 dying from natural causes than unvaccinated individuals. 228

While some of these studies suggest that the BCG vaccine has non-specific effects on 229 morbidity and mortality, none of the study designs can establish a causal relationship<sup>2</sup> because 230 they do not sufficiently account for confounding due to factors such as the healthy vaccinee 231 bias (Schaltz-Buchholzer, Kjær Sørensen, et al., 2021). The healthy vaccinee bias occurs if 232 healthy children, and thus children with a higher overall probability of survival, are more likely 233 to receive the vaccine than unhealthy children. The decision to not administer the vaccine can 234 be based on concerns around side effects or because these parents have a lower health service 235 uptake in general. Comparing vaccinated to unvaccinated individuals without considering 236 systematic differences in characteristics that are correlated with the decision to vaccinate can 237 result in an over- or underestimation of the vaccine's true non-specific effects. We address this 238 239 knowledge gap by applying quasi-experimental methods that take advantage of the sudden

 $<sup>^2</sup>$  Giamarellos-Bourboulis et al. (2020) conducted a clinical trial with 202 participants aged 65 years and older who either received the BCG vaccine or a placebo at hospital discharge. The trial showed that the short-term risk of infection was reduced among the treatment group. However, these results cannot be generalized to a broader population nor long-term survival.

240 discontinuation of compulsory vaccination to estimate the causal effect of BCG vaccination on
241 survival into adulthood.

242

## 243 **Data and methods**

244 **Data** 

We screened all available information on the BCG Atlas to identify countries that would be 245 eligible for inclusion in our study (Zwerling et al., 2011). First, we identified all countries 246 which had a change in vaccination policy, moving from compulsory to optional vaccination as 247 potential natural experiments. Next, we screened the documentation provided on each of these 248 countries in the Human Mortality Database (HMD) as of January 19, 2022 to identify which 249 250 of these countries have available data for all years in our study period (University of California, 251 Berkeley, and Max Planck Institute for Demographic Research). We identified six potential countries with a change in vaccination policy that also had data available in the HMD (Austria, 252 253 Denmark, Finland, France, Great Britain, Norway, Sweden). We chose Sweden as most suitable for the following reasons: (1) there was a sharp discontinuation of compulsory 254 vaccinations in 1975 and BCG vaccine coverage dropped from 95% before 1975 to 2% in the 255 years following the discontinuation (Romanus, 2006); and (2) Sweden was the first country to 256 abolish a nationwide policy and discontinue the BCG vaccine. Thus, Sweden allows for the 257 258 maximum observation period in terms of survival into adulthood.

One of our study designs, the multi-period DiD, additionally requires selecting a control country that followed a similar survival trajectory prior to the discontinuation of BCG vaccination in Sweden but that did not discontinue vaccines at the same or similar time as Sweden. Based on this criterion, we selected Norway as the most suitable counterfactual

country for the DiD analyses.<sup>3</sup> For both Sweden and Norway, we accessed data on the number of births and age-specific death rates for each birth cohort born from 1846 to 1988 from the Human Mortality Database. To minimize confounding from the aftermath of World War II, we only included birth cohorts born in 1950 or later. Thus, our observation period covers cohorts born from 1950 to 1988, which allows us to study the impact of BCG vaccination on the cohort probability of survival to age 30 (for those born in the final 1988 birth cohort, we have data on their survival up to the year 2018, when cohort members turned 30).

Unfortunately, we were not able to use Swedish register data, which is commonly used 270 271 in demographic analyses of the Swedish population, (Barclay & Kolk, 2018; Bucher-Koenen, Farbmacher, Guber, & Vikström, 2020: Cook, Fletcher, & Forgues, 2019; Helgertz 272 & Bengtsson, 2019; Lazuka, 2019; Oudin Åström, Edvinsson, Hondula, Rocklöv, & 273 274 Schumann, 2016) for the following two reasons: (1) our analysis requires survival data for cohorts born several years before the BCG discontinuation in 1975, but the Demographic Data 275 Base only includes data from 1973 and later. (2) It is not currently possible to link the 276 Demographic Data Base to BCG vaccination data. 277

278

#### 279 **Data preparation**

Our outcome of interest is the probability of survival to age 30 in each birth cohort by country. Constructing this outcome requires information on the number of individuals that survived to age 30 in each cohort. The HMD data include cohort age-specific death rates but not the total number of deaths that occurred in a birth cohort by age. We, therefore, had to convert the age-

<sup>&</sup>lt;sup>3</sup> If there were multiple potential counterfactual countries, we could have combined them using a synthetic control approach. This was our initial intention after identifying seven potential control countries: Austria, Finland, France, Great Britain, Japan, Norway, and Portugal. Based on initial synthetic control analyses, we proceeded with the multi-period DiD rather than the synthetic control approach as no country other than Norway had a pre-trend that resembled Sweden, and as such the synthetic control approach gave nearly 100% of the weight to Norway.

specific death rates to death counts. We did this through the following procedure. First, we 284 converted the cohort age-specific mortality rates to the age-specific probabilities of survival 285 using the standard life-table approach (Preston, Heuveline, & Guillot, 2001). Second, we 286 generated a dataset with the number of observations equal to the number of births in a cohort. 287 We then generated a variable for "alive at age 30" and used the cohort life table probability of 288 289 survival from birth to age 30 to determine what share of this initial birth cohort survived to age 290 30, and correspondingly assigned values to the "alive at age 30" variable. For example, if among the 115,414 births for the 1950 birth cohort, the cohort-life table probability of survival 291 292 to age 30 was 90%, we would assign values of 1 for "alive at age 30" to  $(0.9 \times 111,414 = )$ 100,273 observations. This procedure was repeated for each birth cohort, resulting in a final 293 dataset of 4,152,211 observations, which equals the total number of births in Sweden from 294 295 1950 to 1988. We repeated this approach to generate individual-level datasets for Norway as well as separately for males and females in each country. 296

297

## 298 Identification strategies

299 We used two complementary quasi-experimental designs to assess the effect of the sharp BCG 300 discontinuation in Sweden on cohort survival to age 30: the regression discontinuity design 301 (RDD) and the multi-period difference in differences (DiD) approach. The RDD estimates the 302 causal effect of an intervention or policy in situations where exposure to the intervention/policy is based on whether individuals fall on one side or another of some type of cut-off. This cut-303 304 off point is usually referred to as the "threshold" and the continuous variable on which the cut off is based is known as the "running variable." For example, individuals may be eligible for 305 free health care (the policy) based on whether their income (the running variable) is below the 306 307 poverty line (the threshold). In such circumstances, the RDD design estimates the causal effect 308 of the policy under the assumption that in the absence of the treatment, the relationship between

the running variable and an outcome would have evolved continuously. Heuristically, this can be expressed that those just below the threshold are, on average, identical in all characteristics to those just above the threshold. The only difference being that those above the threshold receive the treatment (in our study, this would be not receiving BCG vaccination). Importantly, the RDD estimates the local average treatment effect (LATE) at the threshold value.

314 For our analysis, we followed the continuity-based RDD approach described by 315 Cattaneo et al. (2019). The first assumption of an RDD is that the probability of being treated changes discontinuously at the specified threshold. In our analysis, the running variable is year 316 317 of birth and the threshold is 1976, the birth year of the first cohort for which the BCG vaccine 318 was not mandatory anymore. There are no yearly data on BCG coverage for the years around 319 the threshold. However, Romanus et al. (2006) report that BCG vaccine coverage dropped from 320 95% to 2% in the five years following the discontinuation, which shows that the probability of 321 receiving the BCG vaccine decreased sharply at the threshold. A second assumption is that the outcome would be continuous at the threshold in the absence of the treatment. In other words, 322 323 there was no substantial change in the probability of survival to age 30 induced by an event other than the BCG vaccination discontinuation. To our knowledge, there have been no major 324 shifts in policies nor national-level events, such as natural disasters, which could have affected 325 326 the probability of survival of the cohorts born just before the discontinuation differently to 327 those born just after. Finally, for the RDD approach to be valid, individuals should not 328 systematically sort around the threshold with the aim to obtain or avoid the treatment. We 329 assess this risk to be negligible in the context of our study as we consider it unlikely that parents accurately anticipated and based their family planning on the future BCG policy change. This 330 331 is supported by the data, which shows no clustering of births neither above nor below the threshold (Figure S 1). 332

We followed the current best practice for RDD estimation (Cattaneo et al., 2019). This includes using a local linear model (to prevent overfitting the data), including triangular Kernel weights (to give more weight to observations closer to the threshold), and a data-driven approach for identifying the bandwidth around the threshold (to remove arbitrary bandwidth selection and potential manipulation of the bandwidth size by researchers) (Imbens & Kalyanaraman, 2012). For inference, we used robust bias-corrected standard errors and confidence intervals (Cattaneo et al., 2019). Our estimation model is:

340 
$$Y_i = \beta_0 + \beta_1 X_i + \beta_2 D_i + \beta_3 X_i D_i + \varepsilon_i$$

Here  $Y_i$  is the probability of survival to age 30 for new born *i*,  $X_i$  is a continuous measure of year of birth (the running variable), and  $D_i$  is a binary indicator that takes the value 1 if a birth cohort was born after the discontinuation of mandatory BCG vaccination (Cunningham, 2021).  $\beta_3$  is the causal effect of the discontinuation of the BCG vaccine on survival to age 30 for the cohort born in the threshold year, i.e. 1976.

While the RDD estimates the effect of the BCG discontinuation for the cohort born in the threshold year, it could be the case that the effect only emerges after several birth cohorts (for example if it took a few birth cohorts to fully discontinue the vaccine). Although it is unlikely, it could also be the case that another shock unrelated to BCG discontinuation occurred over the same period of the discontinuation. To investigate the effect of BCG vaccination in the case of these two scenarios, we conducted a multi-period DiD model (sometimes also referred to as leads and lags model) with Norway as the comparison country.

The multi-period DiD estimates the effect of the vaccine discontinuation by comparing the probability of survival in Sweden and Norway in each birth cohort accounting for temporal trends, i.e. the general positive trend in the probability of survival, as well as the baseline difference between the two countries. The central identifying assumption of the multi-period DiD is that in the absence of BCG discontinuation, the cohort probability of survival to age 30

in Sweden would follow the same trend as the cohort probability of survival to age 30 in 358 Norway (the so-called parallel trends assumption). This assumption is commonly assessed by 359 comparing the trends in the outcome variable in the pre-treatment period. While we formally 360 assess this assumption later, the visual evidence presented in Figure 1 shows that among several 361 potential comparison countries, the cohort mortality trends in Norway most closely mirrored 362 those in Sweden. By estimating the effect of BCG discontinuation on survival for multiple birth 363 364 cohorts born after the discontinuation – and not just the 1976 birth cohort as in the RDD - this approach reveals whether the effect wanes or intensifies over time or whether there is a lag in 365 366 the effect and only cohorts born some years after the discontinuation are affected.

367

The multi-period DiD regression model is set up as follows:

368 
$$Y_{ct} = \beta_0 + \beta_1 \mu_c + \beta_2 \lambda_t + \beta_3 \mu_c \lambda_t + \varepsilon_{ct}$$

with c indexing countries and t indexing years (Cunningham, 2021).  $\mu_c$  is a country fixed effect 369 which accounts for the baseline difference in the probability of survival between the treatment 370 371 (Sweden) and control (Norway) countries.  $\lambda_t$  is a vector of year fixed effects which account for the time trend common to both countries (1975, the year of the BCG vaccine discontinuation, 372 is the reference year).  $\mu_t \lambda_t$  is a vector of the interaction between the country and year dummies 373 374 and can be interpreted as the treatment effect for each of the birth cohorts. Importantly, the coefficients on the country-year interaction terms for cohorts born before 1975 provides a test 375 376 of the parallel trends assumption (these coefficients should be close to 0). Lastly, rather than estimate treatment effects for each birth cohort born after the BCG discontinuation, we can also 377 378 estimate a common treatment effect for all birth cohorts by interacting the country dummy with 379 a post dummy (=1 for all cohorts born in or after the year of discontinuation) and including year fixed effects as individual dummy variables (Angrist & Pischke, 2008): 380

381 
$$Y_c = \beta_0 + \beta_1 \mu_c + \beta_2 \lambda_t + \beta_3 \mu_c * Post + \beta_4 Post + \varepsilon_{ct}$$

## 383 **Results**

The final data include one observation per person born from 1950 to 1988. For Sweden, this 384 385 includes 4,152,211 people in total (2,137,830 men and 2,014,381 women), ranging from 91,780 in the cohort born in 1983 to 123,354 in 1966. In Norway, 2,326,387 people were born in this 386 period (1,196,500 men and 1,129,887 women), ranging from 49,937 in 1983 to 67,746 in 1969. 387 Figure 2 shows the probability of survival to age 30 in Sweden for birth cohorts born between 388 1950 to 1988. Survival to age 30 increased from 95.9% in the 1950 birth cohort to 98.6% in 389 390 the 1988 birth cohort. Across all years, the probability of survival was higher among women 391 than men. For example, in 1975 the probability of survival to age 30 was 98.6% among women and 97.7% among men. Despite this difference in the absolute level, survival in the female and 392 393 male subpopulations followed a similar trend. Visually, we observe no evidence of an abrupt 394 change in the probability of survival in the whole population when comparing the cohort born in the year of the BCG vaccine discontinuation (98.2% in 1975) and the first cohort for whom 395 396 the vaccine was optional (98.2% in 1976). This smooth trend around 1975 is also present when separately looking at the male and female subpopulations. 397

398

#### 399 **Regression Discontinuity results**

The RDD analysis confirms the results of the visual inspection: we do not find evidence of an 400 401 effect of the BCG vaccination discontinuation on long-term survival in the birth cohort born in 1976. We estimate a precise null effect (0.00 percentage points (pp) (95% CI -0.20 - 0.17)) on 402 the probability of survival to age 30 at the point of BCG vaccination discontinuation (Table 1, 403 Figure 3). As with the visual results, this finding was not driven by just males or females. We 404 405 also find no evidence that BCG vaccine discontinuation affected the probability of survival to age 30 for among the male (0.05pp (-0.17 - 0.25)) or female (0.11pp (-0.46 - 0.15))406 407 subpopulations (Table 1, Figures S 2 and S 3).

408

## 409 Multi-period difference in differences results

While the RDD estimates potential non-specific effects for the cohort born in the year of the 410 vaccine discontinuation, the DiD allows us to generate estimates for each birth cohort and, thus, 411 yields the opportunity to detect lagged effects. The event-study plot in Figure 4 shows the 412 difference in survival between birth cohorts born in Norway and Sweden for each cohort born 413 414 before and after the BCG discontinuation. The coefficients are shown net of an overall level difference in survival between the two countries and a time trend. In support of the parallel 415 416 trends assumption, we find that most point estimates in the pre-discontinuation period are not statistically different from zero (exact values are shown in Table S 1). This suggests that prior 417 to the discontinuation of BCG vaccination in Sweden, both countries were following a parallel 418 419 trend in cohort survival to age 30. The coefficients after the vertical line in 1975 capture any effect of BCG discontinuation on survival in Sweden. Similar to our RDD results, we find no 420 evidence of differences in cohort survival to age 30 in the post-BCG-discontinuation period 421 between individuals born in Sweden and Norway across most birth cohorts. For Swedish 422 cohorts born after 1983, we see some evidence of lower survival to age 30; however, these 423 differences are for cohorts born nearly 10 years after the discontinuation of BCG. For this 424 reason, we consider it more likely that the negative point estimates for younger birth cohorts 425 were caused by other changes at the population level that differed between Norway and Sweden 426 427 at that time rather than being caused by the discontinuation of the BCG vaccine.

By splitting the results by birth cohort, the event-study results may result in underpowered estimates of the effect of BCG discontinuation. When pooling all data from the pre- and post-discontinuation periods, respectively, we find evidence of a very small negative effect of the BCG vaccine on the probability of survival to age 30 by -0.06pp (-0.11 – 0.00) (Table 2). While these results are statistically precise due to our large sample size (over six

million observations), the effects we estimate are extremely small in magnitude at less than a
10th of a percentage point and thus of minimal policy significance. Further, based on the eventstudy plot, this minimal effect is likely driven by the lower survival among the 1983+ birth
cohorts.

We find a similar set of conclusions when examining males and females separately. 437 Among both the male and female population, there was no difference in the probability of 438 439 survival for the cohorts born before the BCG vaccine discontinuation, indicating support for the parallel trend assumption. In the female subpopulation, there was also no difference in the 440 441 probability of survival between Sweden and Norway after the vaccine discontinuation (net of the time and level trends). This visual finding is confirmed in the pooled analysis (0.00pp (-442 (0.07 - 0.07)). In the male subpopulation, the results also suggest that there were no non-specific 443 444 effects of the BCG vaccine on survival. However, as observed in the total population, cohorts born after 1983 in Sweden had a lower probability of survival in Sweden than in Norway. 445 Furthermore, pooling all pre- and post-discontinuation birth cohorts reveals that the probability 446 of survival decreased by 0.11pp (-0.19 - -0.02) among men. 447

It is likely that this result is driven by the youngest birth cohorts, which represent 448 approximately one third of the post-discontinuation birth cohorts, but were born nearly 10 years 449 after the vaccine discontinuation and thus the validity of the DiD assumption that any 450 difference was due to the discontinuation alone for this group is questionable. To test this, we 451 452 restricted our sample to the cohorts born within the MSE optional bandwidth calculated in the RDD analysis, which was +/- six years in the male sample (Table 2). The results show that for 453 the birth cohorts born within the MSE optimal bandwidth, there was no difference in the 454 455 probability of survival between the total, male, and female populations in Sweden and Norway (Table 2). 456

### 458 Sensitivity analyses

We conducted several sensitivity analyses to test the robustness of our results. First, it could be 459 the case that the rate of change of survival across cohorts depends on the absolute level of 460 survival, and that this functional form affects our estimates. To investigate this, we plotted the 461 log probability of survival and found that flattening of the cohort survival trends was not driven 462 by the fact that the probability of survival approached 100% (Figure S 6). Second, the RDD 463 464 estimates whether there was a sudden change in the level of the probability of survival after the BCG vaccine discontinuation. It could, however, also be the case that the discontinuation 465 466 slowed down the rate of change in the increase of the probability of survival to age 30. To investigate this, we applied a Regression Kink Design (RKD). The RKD relies on the same 467 assumptions as the RDD but is applied when there is not a discontinuity in the probability of 468 469 being treated but in its first derivative, i.e. in the slope of the relationship between the treatment 470 and the assignment variable. In the context of our analysis, this would be the case if the probability of receiving the vaccine was still high in 1975, the year of the discontinuation, and 471 only gradually decreased in the following years. Another potential scenario could be that the 472 probability of being vaccinated already declined before the official discontinuation. Rather than 473 causing a shift in the probability of survival, the gradual discontinuation would cause a change 474 in its slope. In the RKD analysis we also found no evidence of an effect of the BCG vaccine 475 discontinuation on the rate of change in the probability of survival in the total and female 476 477 populations (Table 3). Among men, we found evidence of a slight decrease in the rate of change (-0.10 (-0.24 - 0.00)) of mortality. However, although statistically precise, the magnitude of 478 this decrease is extremely small and thus of limited policy significance. Third, to address this 479 480 same issue and the fact that more individuals born in 1975 were born after the discontinuation, (Romanus, 1983) we set the cut-off to be one year earlier (1975 in the RDD 481 and 1974 in the multi-period DiD), which produced consistent results with those of the main 482

analysis (Tables S 2 to S 4, Figures S 7 to S 9). Fourth, in the RDD analysis, the point estimate 483 and inference might depend on the bandwidth within which the LATE is estimated. Increasing 484 the bandwidth will reduce variance as more observations are included in the analysis. However, 485 it increases the bias because these observations are less similar to each other than those closer 486 to the cut-off. Decreasing the bandwidth would have the opposite effect and increase variance 487 while reducing the bias. It was not possible to decrease the bandwidth due to the limited number 488 489 of mass points in our analysis but increasing the bandwidth by one, two, and three years, did not change the results and all point estimates remained statistically insignificant (Table S 5). 490

491

## 492 **Discussion**

There is continued interest in the non-specific effect of the BCG vaccine and whether 493 494 populations should be vaccinated even if there is a low burden of TB (Goodridge et al., 2016). 495 If the BCG vaccine had non-specific effects and increased adult survival among the general population, it could be a simple and cost-effective intervention to improve population health. 496 Mechanistically, such an effect seems plausible since the BCG vaccine is thought to improve 497 general childhood immunity (Cirovic et al., 2020). Other studies focused on other early life 498 conditions also find evidence of life course consequences to changes in early life immunity and 499 500 health (Almond, Currie, & Duque, 2018; Almond & Mazumder, 2005). Using population data and two complementary quasi-experimental methods that take advantage of the sudden 501 discontinuation of the mandatory BCG vaccination in Sweden, we find no evidence for non-502 503 specific effects of the BCG vaccine on the probability of survival to age 30. In other words, up 504 to this age and at the population level, the BCG vaccine does not appear to have substantial protective effects on mortality from diseases other than TB. This result is robust to multiple 505 506 sensitivity and robustness checks and remains valid when estimating the effect separately for the male and female subpopulations. 507

508 Our results are in stark contrast to a previous study from Copenhagen, Denmark, which 509 found that BCG vaccination was associated with an approximately 50% lower probability of survival (Rieckmann, Villumsen, Sørup, et al., 2017). The differences between our studies are 510 511 likely due to residual confounding. In particular, the authors compare children that did and did 512 not receive the vaccination during a period in Denmark when BCG vaccination became 513 voluntary. Thus, parents self-selected their children into vaccination, and it is likely that the 514 decision to vaccinate is related to characteristics that also influence the probability of survival. Such factors could include parental knowledge about the health of their child (as mentioned 515 516 previously, BCG vaccination can have strong side-effects for less healthy children) and the 517 background and socioeconomic status of parents who decide to vaccinate their children compared to those that do not. The authors undertook several steps to adjust for such potential 518 519 sources of confounding; however, there is still a likelihood that the results were driven by unobserved systematic differences between the vaccinated and unvaccinated that affect both 520 the vaccination status and survival since vaccination status was related to a direct parental 521 choice and not a mandatory law as in our study. 522

523 The potential for non-specific effects among some sub-populations raises the question of whether vaccinating an entire population would provide a cost-effective way of realizing all 524 potential non-specific effects without having to target specific population groups. However, 525 526 such an approach would come with trade-offs. First, the intensity of the non-specific effects 527 will depend on when the vaccine is administered. For example, Giaramellos-Bourboulis et al. (2020) suggest that the BCG vaccine, if given just before hospital discharge, increases time to 528 first infection among the elderly. This non-specific effect may not have materialized if the 529 530 vaccine had been given during childhood because adaptions in the innate immune system are only transitory. Thus, to reap all non-specific benefits, the population would have to be 531 532 revaccinated in regular intervals. Second, the BCG vaccine is cost-effective against TB under

533 standard thresholds. However, given the lack of a detectable population-level non-specific effect, it is unlikely to be cost-effective when the objective is to improve population survival 534 in a setting like Sweden. Third, the BCG vaccine can have non-negligible side effects. While 535 the most common side effects are mild and temporary (fever, headache, or soreness on the 536 location where the vaccine was given), less common and more severe side effects are abscesses, 537 538 bone inflammation, or disseminated TB (Raviglione Mario C., 2018). The latter is a particular 539 risk for those who are immunocompromised. Taken together, while BCG vaccination may protect sub-populations, a broad population policy of continued vaccination is unlikely to meet 540 541 conventional cost-effectiveness thresholds and comes with the risk of potentially serious side effects among individuals with a low expected benefit. 542

One important consideration is that our results are for Sweden, a country with a near 543 544 negligible burden of TB and where infectious disease mortality, excluding deaths from Covid-19, is extremely low (The National Board of Health and Welfare, Sweden [Socialstyrelsen], 545 2019). The lack of a strong relationship between early childhood BCG vaccination and adult 546 mortality in this context is not necessarily evidence that changes to early life immunity do not 547 affect adult mortality risk, but rather that such life-course effects may become less important 548 as the general level of infectious mortality in a population decreases. BCG vaccination may 549 have beneficial non-specific effects for individuals at elevated risk of mortality from infectious 550 diseases, such as those in many low- and middle-income countries or for specific at-risk groups 551 within low-TB countries. Evaluating the non-specific effects of BCG vaccination among such 552 populations is an important area of future work. 553

A second important consideration with RDD analyses is that the effect estimate of a treatment or policy applies only to those within the bandwidth around the threshold point. In our case, the RDD estimates the effect of BCG discontinuation on the first birth cohort to not receive the vaccine. If the BCG vaccine protected against infectious diseases, in particular

558 during childhood as suggested by previous studies, there might be a time lag between the discontinuation of the vaccine and the realization of the non-specific effects as younger cohorts 559 become exposed to larger shares of unvaccinated individuals (Biering-Sørensen et al., 2018; 560 Giamarellos-Bourboulis et al., 2020). In this case, cohorts born after infectious diseases have 561 crossed a critical prevalence threshold would be affected by the BCG discontinuation whereas 562 those born during or just after the discontinuation would not. Another reason for lagged effects 563 564 would be a gradual decrease in the BCG coverage over several birth cohorts rather than an abrupt change. However, both these scenarios would be captured in our multi-period DiD 565 566 analysis. Therefore, the null results in both the RDD and the multi-period DiD suggest that there were no immediate nor lagged non-specific effects of the BCG vaccine. 567

Our study has several limitations and considerations. If an exogenous factor, which we 568 569 did not account for in the analysis, caused a decline (increase) in the probability of survival at 570 the same time as the discontinuation of BCG vaccination, it could have offset potential beneficial (harmful) non-specific effects of the BCG vaccine. To rule this out, we undertook 571 several steps. First, in our sensitivity analysis, we varied the cut-off year. The conclusions of 572 both quasi-experimental method analyses remain unaffected by this change. Second, we 573 conducted an extensive search to identify potential large-scale changes in the health, economic, 574 and political sectors in Sweden and Norway. We found no evidence of any changes in the living 575 576 situation in both countries, which could have differentially affected survival at the population 577 level in either of the countries. Another aspect to consider is that the vaccinia vaccine was discontinued in Sweden in 1976, i.e. shortly after the BCG vaccine (The Public Health Agency 578 of Sweden, 2020). However, given the fact that the vaccinia vaccine was discontinued around 579 580 the same time in Norway and we also find no statistically significant effect in the multi-period DiD analysis, we do not expect the vaccinia discontinuation to have biased our results 581 (Norwegian Institute of Public Health, 2010). Because of data constraints, we only estimated 582

the effect of the BCG discontinuation on survival to age 30. Including older ages, in particular the elderly where infectious diseases are more detrimental, might yield additional insights. For the same data limitations, our analysis does not assess whether the BCG vaccine protects against COVID-19 because cohort death rates are only available up to 2018.

587 Our study finds that the BCG vaccination did not have non-specific effects on long-588 term survival in Sweden. Thus, our research suggests that re-introducing or continuing national 589 mandatory BCG vaccination in countries with similar population mortality and morbidity 590 profiles as Sweden is unlikely to lead to substantial or cost-effective improvements in 591 population health.

#### 593 References

- Abubakar, I., Pimpin, L., Ariti, C., Beynon, R., Mangtani, P., Sterne, J. A. C. [J. A. C.], ...
  Rodrigues, L. C. (2013). Systematic review and meta-analysis of the current evidence on the
- 596 duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. *Health*
- 597
   Technology
   Assessment
   (Winchester,
   England),
   17(37),
   1-372,
   v-vi.

   509
   1.11
   110
   2210.14
   17270
- 598 <u>https://doi.org/10.3310/hta17370</u>
- Almond, D., Currie, J., & Duque, V. (2018). Childhood Circumstances and Adult Outcomes: Act II.
   *Journal of Economic Literature*, 56(4), 1360–1446. <u>https://doi.org/10.3386/w23017</u>
- Almond, D., & Mazumder, B. (2005). The 1918 Influenza Pandemic and Subsequent Health Outcomes:
  An Analysis of SIPP Data. *The American Economic Review*, 95(2), 258–262.
- Angrist, J. D., & Pischke, J.-S. (2008). *Mostly Harmless Econometrics: An Empiricist's Companion*.
  Princeton University Press.
- Barberis, I., Bragazzi, N. L., Galluzzo, L., & Martini, M. (2017). The history of tuberculosis: from the
  first historical records to the isolation of Koch's bacillus. *J Prev Med Hyg*, 58(1), E9-E12.
- 607 Barclay, K. J., & Kolk, M. (2018). Birth Intervals and Health in Adulthood: A Comparison of Siblings
- Using Swedish Register Data. *Demography*, 55(3), 929–955. <u>https://doi.org/10.1007/s13524-018-</u>
   0673-8
- Bergström, M., Mäkinen, M., & Romanus, V. [Victoria] (2001). Vaccinationsstatistik från BVC: *Rapporter insända januari 2000 och januari 2001 gällande barn födda 1997 och 1998.*
- 612 Biering-Sørensen, S., Jensen, K. J., Monterio, I., Ravn, H., Aaby, P., & Benn, C. S. [Christine Stabell]
- 613 (2018). Rapid Protective Effects of Early BCG on Neonatal Mortality Among Low Birth Weight
- Boys: Observations From Randomized Trials. *The Journal of Infectious Diseases*, 217(5), 759–766.
- 615 https://doi.org/10.1093/infdis/jix612
- Bonanni, P. (1999). Demographic impact of vaccination: a review. *Vaccine*, *17*, S120-S125.
   https://doi.org/10.1016/S0264-410X(99)00306-0
- 618 Böttiger, M., Romanus, V. [V.], Verdier, C. de, & Boman, G. (1982). Osteitis and other complications
- 619 caused by generalized BCG-itis. Experiences in Sweden. Acta Pædiatrica, 71(3), 471–478.

- 620 Breiman, R. F., Streatfield, P. K., Phelan, M., Shifa, N., Rashid, M., & Yunus, M. (2004). Effect of
- 621 infant immunisation on childhood mortality in rural Bangladesh: analysis of health and demographic
- 622 surveillance data. *The Lancet*, 364(9452), 2204–2211. <u>https://doi.org/10.1016/S0140-</u>
  623 6736(04)17593-4
- 624 Bucher-Koenen, T., Farbmacher, H., Guber, R., & Vikström, J. (2020). Double Trouble: The Burden
- 625 of Child-rearing and Working on Maternal Mortality. *Demography*, 57(2), 559–576.
   626 <u>https://doi.org/10.1007/s13524-020-00868-6</u>
- Case, A., & Paxson, C. (2010). Causes and Consequences of Early Life Health. *Demography*, 47(1).
   <a href="https://doi.org/10.3386/w15637">https://doi.org/10.3386/w15637</a>
- 629 Castro, M. J. de, Pardo-Seco, J., & Martinón-Torres, F. (2015). Nonspecific (Heterologous) Protection
- 630 of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis.
- 631 *Clinical Infectious Diseases*, 60(11), 1611–1619. <u>https://doi.org/10.1093/cid/civ144</u>
- Cattaneo, M. D., Idrobo, N., & Titiunik, R. (2019). *A practical introduction to regression discontinuity designs: Foundations*. Cambridge University Press.
- 634 Central Bureau of Statistics Norway (1961). *Trend of mortality and causes of death in Norway 1856–*635 1955. Oslo.
- 636 Chisholm, R. H., Trauer, J. M., Curnoe, D., & Tanaka, M. M. (2016). Controlled fire use in early
- 637 humans might have triggered the evolutionary emergence of tuberculosis. Proceedings of the
- 638 *National Academy of Sciences*, *113*(32), 9051–9056.
- 639 Cirovic, B., Bree, L. C. J. de, Groh, L., Blok, B. A., Chan, J., van der Velden, W. J. F. M., ...
- 640 Schlitzer, A. (2020). Bcg Vaccination in Humans Elicits Trained Immunity via the Hematopoietic
- 641 Progenitor Compartment. Cell Host & Microbe, 28(2), 322-334.e5.
   642 https://doi.org/10.1016/j.chom.2020.05.014
- 643 Committee on Government Operations, United States Congress Senate. *The status of world health in* 644 *outline text and chart.*
- 645 Cook, C. J., Fletcher, J. M., & Forgues, A. (2019). Multigenerational Effects of Early-Life Health
- 646 Shocks. *Demography*, 56(5), 1855–1874. https://doi.org/10.1007/s13524-019-00804-3

- 647 Cunningham, S. (2021). Causal Inference. Yale University Press.
- 648 Cutler, D., & Miller, G. (2005). The role of public health improvements in health advances: The
- twentieth-century United States. *Demography*, 42(1), 1–22. <u>https://doi.org/10.1353/dem.2005.0002</u>
- Daniel, T. M. (2006). The history of tuberculosis. Respiratory Medicine, 100(11), 1862-1870.
- 651 <u>https://doi.org/10.1016/j.rmed.2006.08.006</u>
- Dara, M., Acosta, C. D., Rusovich, V., Zellweger, J. P., Centis, R., & Migliori, G. B. (2014). Bacille
- 653 Calmette-Guérin vaccination: The current situation in Europe. The European Respiratory Journal,
- 654 *43*(1), 24–35. <u>https://doi.org/10.1183/09031936.00113413</u>
- Dockrell, H. M., & Smith, S. G. (2017). What Have We Learnt about BCG Vaccination in the Last 20
- 656 Years? Frontiers in Immunology, 8. <u>https://doi.org/10.3389/fimmu.2017.01134</u>
- Drummond, M., Chevat, C., & Lothgren, M. (2007). Do we fully understand the economic value of
  vaccines? *Vaccine*, 25(32), 5945–5957. https://doi.org/10.1016/j.vaccine.2007.04.070
- Elguero, E. [Eric], Simondon, K. B., Vaugelade, J. [Jacques], Marra, A., & Simondon, F. [François]
- 660 (2005). Non-specific effects of vaccination on child survival? A prospective study in Senegal.
- 661 Tropical Medicine & International Health, 10(10), 956–960. <u>https://doi.org/10.1111/j.1365-</u>
  662 3156.2005.01479.x
- Elo, I. T., & Preston, S. H. (1992). Effects of Early-Life Conditions on Adult Mortality: A Review. *Population Index*, 58(2), 186–212.
- 665 Garly, M.-L., Martins, C. L., Balé, C., Baldé, M. A., Hedegaard, K. L., Gustafson, P., ... Aaby, P.
- 666 (2003). BCG scar and positive tuberculin reaction associated with reduced child mortality in West
- 667 Africa. Vaccine, 21(21-22), 2782–2790. https://doi.org/10.1016/S0264-410X(03)00181-6
- 668 Giamarellos-Bourboulis, E. J., Tsilika, M., Moorlag, S., Antonakos, N., Kotsaki, A., Domínguez-
- 669 Andrés, J., ... Netea, M. G. (2020). Activate: Randomized Clinical Trial of BCG Vaccination
- 670 against Infection in the Elderly. *Cell*, 183(2), 315-323.e9. <u>https://doi.org/10.1016/j.cell.2020.08.051</u>

- 671 Goodridge, H. S., Ahmed, S. S., Curtis, N., Kollmann, T. R., Levy, O., Netea, M. G., . . . Wilson, C. B.
- 672 (2016). Harnessing the beneficial heterologous effects of vaccination. *Nature Reviews Immunology*,
- 673 *16*(6), 392–400. <u>https://doi.org/10.1038/nri.2016.43</u>
- Helgertz, J., & Bengtsson, T. (2019). The Long-Lasting Influenza: The Impact of Fetal Stress During
- the 1918 Influenza Pandemic on Socioeconomic Attainment and Health in Sweden, 1968-2012.
- 676 *Demography*, 56(4), 1389–1425. <u>https://doi.org/10.1007/s13524-019-00799-x</u>
- 677 Hershkovitz, I., Donoghue, H. D., Minnikin, D. E., May, H., Lee, O. Y.-C., Feldman, M., ... Bar-
- 678 Gal, G. K. (2015). Tuberculosis origin: The Neolithic scenario. *Tuberculosis (Edinburgh, Scotland)*,
- 679 95 Suppl 1, S122-6. <u>https://doi.org/10.1016/j.tube.2015.02.021</u>
- Higgins, J. P. T., Soares-Weiser, K., López-López, J. A., Kakourou, A., Chaplin, K.,
  Christensen, H., ... Reingold, A. L. (2016). Association of BCG, DTP, and measles containing
- 682 vaccines with childhood mortality: Systematic review. *BMJ (Clinical Research Ed.)*, 355, i5170.
- 683 <u>https://doi.org/10.1136/bmj.i5170</u>
- Imbens, G., & Kalyanaraman, K. (2012). Optimal Bandwidth Choice for the Regression Discontinuity
  Estimator. *The Review of Economic Studies*, 79(3), 933–959. https://doi.org/10.1093/restud/rdr043
- 686 Karafillakis, E., Hassounah, S., & Atchison, C. (2015). Effectiveness and impact of rotavirus vaccines
- 687 in Europe, 2006-2014. Vaccine, 33(18), 2097–2107. <u>https://doi.org/10.1016/j.vaccine.2015.03.016</u>
- 688 Kölmel, K. F. [K. F.], Grange, J. M. [J. M.], Krone, B. [B.], Mastrangelo, G. [G.], Rossi, C. R.,
- 689 Henz, B. M., ... Pfahlberg, A. [A.] (2005). Prior immunisation of patients with malignant
- 690 melanoma with vaccinia or BCG is associated with better survival. An European Organization for
- 691 Research and Treatment of Cancer cohort study on 542 patients. *European Journal of Cancer*
- 692 (Oxford, England : 1990), 41(1), 118–125. <u>https://doi.org/10.1016/j.ejca.2004.09.023</u>
- Lamm, D. L., & Morales, A. (2021). A BCG success story: From prevention of tuberculosis to optimal
  bladder cancer treatment. *Vaccine*, *39*(50), 7308–7318.
  https://doi.org/10.1016/j.vaccine.2021.08.026

- 696 Lankes, H. A., Fought, A. J., Evens, A. M., Weisenburger, D. D., & Chiu, B. C.-H. (2009).
- 697 Vaccination history and risk of non-Hodgkin lymphoma: A population-based, case-control study.
- 698 *Cancer Causes & Control : CCC*, 20(5), 517–523. <u>https://doi.org/10.1007/s10552-008-9259-x</u>
- 699 Lazuka, V. (2019). Early-Life Assets in Oldest-Old Age: Evidence From Primary Care Reform in Early
- Twentieth Century Sweden. *Demography*, *56*(2), 679–706.
- Lehmann, D., Vail, J., Firth, M. J., Klerk, N. H. de, & Alpers, M. P. (2005). Benefits of routine
- immunizations on childhood survival in Tari, Southern Highlands Province, Papua New Guinea.
- 703 International Journal of Epidemiology, 34(1), 138–148. <u>https://doi.org/10.1093/ije/dyh262</u>
- Lönnroth, K., Jaramillo, E., Williams, B. G., Dye, C., & Raviglione, M. (2009). Drivers of tuberculosis
- pidemics: The role of risk factors and social determinants. Social Science & Medicine, 68(12),
- 706 2240–2246. <u>https://doi.org/10.1016/j.socscimed.2009.03.041</u>
- Masters, R. K. (2018). Economic Conditions in Early Life and Circulatory Disease Mortality.
   *Population and Development Review*, 44(3), 519–553. https://doi.org/10.1111/padr.12174
- Mayr, A. (2004) Taking Advantage of the Positive Side-Effects of Smallpox Vaccination. *Journal of Veterinary Medicine*, *B51*(5), 199-201
- 711 McEnry, M., & Palloni, A. (2010). Early life exposures and the occurrence and timing of heart disease
- among the older adult Puerto Rican population. *Demography*, 47(1), 23–43.
- 713 Mercer, A. J. (1985). Smallpox and Epidemiological-Demographic Change in Europe: The Role of
- 714 Vaccination. *Population Studies*, *39*(2), 287–307.
- 715 Michiels, B., Govaerts, F., Remmen, R., Vermeire, E., & Coenen, S. (2011). A systematic review of the
- evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups.
- 717 *Vaccine*, 29(49), 9159–9170. <u>https://doi.org/10.1016/j.vaccine.2011.08.008</u>
- 718 Moorlag, S. J., Arts, R. J. W., van Crevel, R., & Netea, M. G. (2019). Non-specific effects of BCG
- 719 vaccine on viral infections. *Clinical Microbiology and Infection*, 25(12), 1473–1478.
- 720 https://doi.org/10.1016/j.cmi.2019.04.020

- 721 Muhoza, P., Danowaro-Holliday, C., Diallo, M. D., Murphy, P., Sodha, S. V., Requejo, J. H., &
- Wallace, A. S. (2021). Routine Vaccination Coverage Worldwide, 2020. *Morbidity and Mortality Weekly Report*, 70(43).
- 724 Murray, J. F. (2001). A thousand years of pulmonary medicine: Good news and bad. The European
- 725 *Respiratory Journal*, 17(3), 558–565. <u>https://doi.org/10.1183/09031936.01.17305580</u>
- 726 Nankabirwa, V., Tumwine, J. K., Mugaba, P. M., Tylleskär, T., & Sommerfelt, H. (2015). Child
- survival and BCG vaccination: A community based prospective cohort study in Uganda. *BMC*
- 728 Public Health, 15, 175. <u>https://doi.org/10.1186/s12889-015-1497-8</u>
- 729 The National Board of Health and Welfare, Sweden (2019). Statistikdatabas för dödsorsaker (Statistics
- 730 database for causes of death). Retrieved from <u>https://sdb.socialstyrelsen.se/if\_dor/val.aspx</u>
- 731 Norwegian Institute of Public Health. *Norge tuberkulinstatus* 9. *Klasse* 1975-1999.
- Norwegian Institute of Public Health (2008). Utredning om bruk av BCG-vaksine i Norge [Study on the
  use of BCG vaccine in Norway].
- Norwegian Institute of Public Health (2010). The history of the Norwegian Institute of Public Health.
- 735 Retrieved from <u>https://www.fhi.no/en/about/this-is-the-norwegian-institute-of-public-</u>
- 736 <u>health/history-of-the-norwegian-institute-/</u>
- Norwegian Institute of Public Health (2016). Tuberculosis (TB) in Norway fact sheet. Retrieved from
   https://www.fhi.no/en/id/infectious-diseases/TB/tuberculosis-tb-in-norway---fact-sh/
- Oudin Åström, D., Edvinsson, S., Hondula, D., Rocklöv, J., & Schumann, B. (2016). On the association
  between weather variability and total and cause-specific mortality before and during
  industrialization in Sweden. *Demographic Research*, 35, 991–1010.
  https://doi.org/10.4054/DemRes.2016.35.33
- Palloni, A., & Souza, L. (2013). The Fragility of the future and the tug of the past: Longevity in Latin
  America and the Caribbean. *Demographic Research*, 29, 543–578.
  https://doi.org/10.4054/DemRes.2013.29.21

- 746 Pfahlberg, A. [Annette], Kölmel, K. F. [Klaus F.], Grange, J. M. [John M.], Mastrangelo, G.
- 747 [Giuseppe], Krone, B. [Bernd], Botev, I. N. [Ivan N.], ... Gefeller, O. [Olaf] (2002). Inverse
- association between melanoma and previous vaccinations against tuberculosis and smallpox: Results
- of the FEBIM study. The Journal of Investigative Dermatology, 119(3), 570–575.
- 750 <u>https://doi.org/10.1046/j.1523-1747.2002.00643.x</u>
- 751 Preston, S. H., Heuveline, P., & Guillot, M. (2001). *Demography: measuring and modeling population*
- 752 *processes*. Blackwell Publishing.
- 753 The Public Health Agency of Sweden (2020). Previous Swedish vaccination programmes. Retrieved
- from <u>https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-</u>
- 755 <u>disease-control/vaccinations/previous-swedish-vaccination-programmes/</u>
- 756 Raviglione Mario C. (2018). Tuberculosis. In J. L. Jameson, A. S. Fauci, D. L. Kasper, S. L. Hauser,
- D. L. Longo, & J. Loscalzo (Eds.), *Harrison's Principles Of Internal Medicine* (20<sup>th</sup> ed.). McGrawHill Education.
- Rieckmann, A., Meyle, K.D., Rod, N.H., Baker, J.L., Stabell Benn, C., Aaby, P., Sørup, S. (2019).
  Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults
- followed from 18 to 49 years. *Vaccine*, *37*(44), 6730–6736.
- Rieckmann, A., Villumsen, M., Jensen, M. L., Ravn, H., Da Silva, Z. J., Sørup, S., ... Aaby, P. (2017).
- The Effect of Smallpox and Bacillus Calmette-Guérin Vaccination on the Risk of Human
  Immunodeficiency Virus-1 Infection in Guinea-Bissau and Denmark. *Open Forum Infectious Diseases*, 4(3), ofx130.
- Rieckmann, A., Villumsen, M., Sørup, S., Haugaard, L. K., Ravn, H., Roth, A., ... Aaby, P. (2017).
- 767 Vaccinations against smallpox and tuberculosis are associated with better long-term survival: A
- Danish case-cohort study 1971-2010. International Journal of Epidemiology, 46(2), 695–705.
  https://doi.org/10.1093/ije/dyw120
- Roberts, K., Alberts, Bruce, Johnson, Alexander, Lewis, J., Raff, M., & Walter, P. (2015). *Molecular Biology of the Cell*. Taylor & Francis.

- Romanus, V. [V.] (1983). Childhood tuberculosis in Sweden. An epidemiological study made six years
- after the cessation of general BCG vaccination of the newborn. Retrieved from
  https://pubmed.ncbi.nlm.nih.gov/6604357/
- Romanus, V. [V.] (2006). Selective BCG vaccination in a country with low incidence of tuberculosis
  (Eurosurveillance No. 3).
- Roth, A., Gustafson, P., Nhaga, A., Djana, Q., Poulsen, A., Garly, M.-L., ... Aaby, P. (2005). Bcg
- vaccination scar associated with better childhood survival in Guinea-Bissau. *International Journal*
- 779 *of Epidemiology*, *34*(3), 540–547. <u>https://doi.org/10.1093/ije/dyh392</u>
- Sakari Härö, A. (1994). Cohort approach in tuberculosis surveillance: comparison of the situation in
  Sweden and Finland. *Tubercle and Lung Disease*, 4(75), 271–282.
- 782 Schaltz-Buchholzer, F., Aaby, P., Monteiro, I., Camala, L., Faurholt Simonsen, S., Nørtoft
- 783 Frankel, H., ... Bjerregaard-Andersen, M. (2021). Immediate Bacille Calmette-Guérin Vaccination
- to Neonates Requiring Perinatal Treatment at the Maternity Ward in Guinea-Bissau: A Randomized
- 785 Controlled Trial. *The Journal of Infectious Diseases*, 224(11), 1935–1944.
  786 https://doi.org/10.1093/infdis/jiab220
- 787 Schaltz-Buchholzer, F., Kjær Sørensen, M., Benn, C. S. [Christine Stabell], & Aaby, P. (2021). The
- introduction of BCG vaccination to neonates in Northern Sweden, 1927-31: Re-analysis of historical
- data to understand the lower mortality among BCG-vaccinated children. *Vaccine*. Advance online
- 790 publication. <u>https://doi.org/10.1016/j.vaccine.2021.06.006</u>
- Statistics Norway. Deaths, by sex, age and detailed cause of death (closed time series) 1969 2012.
  Retrieved from https://www.ssb.no/en/statbank/table/08880/
- 793 Steenhuis, T. J., van Aalderen, W. M. C., Bloksma, N., Nijkamp, F. P., van der Laag, J., van
- Loveren, H., . . . Hoekstra, M. O. (2008). Bacille-Calmette-Guerin vaccination and the development
- 795 of allergic disease in children: A randomized, prospective, single-blind study. *Clinical and*
- 796 *Experimental Allergy*, 38(1), 79–85. <u>https://doi.org/10.1111/j.1365-2222.2007.02859.x</u>
- 797 Thysen, S. M., Benn, C. S. [Christine Stabell], Gomes, V. F., Rudolf, F., Wejse, C., Roth, A., ...
- Fisker, A. (2020). Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed

- children: A prospective cohort study. *BMJ Open*, *10*(2), e035595. <u>https://doi.org/10.1136/bmjopen-</u>
  2019-035595
- 801 Tverdak, A., & Funnemark, E. (1988). Protective effect of BCG vaccination in Norway 1956-73.
  802 *Tubercle*, 69, 119–123.
- 803 University of California, Berkeley, and Max Planck Institute for Demographic Research. The Human
   804 Mortality Database (HMD). Retrieved from www.mortality.org
- 805 Van den Berg, G. J., Doblhammer-Reiter, G., & Christensen, K. (2011). Being Born Under Adverse
- 806 Economic Conditions Leads to a Higher Cardiovascular Mortality Rate Later in Life: Evidence
- 807 Based on Individuals Born at Different Stages of the Business Cycle. *Demography*, 48(2), 507–530.
- 808 Vaugelade, J. [J.], Pinchinat, S., Guiella, G., Elguero, E. [E.], & Simondon, F. [F.] (2004). Non-specific
- 809 effects of vaccination on child survival: Prospective cohort study in Burkina Faso. *BMJ (Clinical*
- 810 *Research Ed.*), 329(7478), 1309. <u>https://doi.org/10.1136/bmj.38261.496366.82</u>
- 811 Villumsen, M., Jess, T., Sørup, S., Ravn, H., Sturegård, E., Benn, C. S. [Christine Stabell], . . . Roth, A.
- 812 (2013). Risk of inflammatory bowel disease following Bacille Calmette-Guérin and smallpox
- 813 vaccination: A population-based Danish case-cohort study. *Inflammatory Bowel Diseases*, 19(8),
- 814 1717–1724. <u>https://doi.org/10.1097/MIB.0b013e318281f34e</u>
- 815 Villumsen, M., Sørup, S., Jess, T., Ravn, H., Relander, T., Baker, J. L. [Jennifer L.], ... Roth, A.
- 816 (2009). Risk of lymphoma and leukaemia after bacille Calmette-Guérin and smallpox vaccination:
- 817 A Danish case-cohort study. Vaccine, 27(49), 6950–6958.
- 818 <u>https://doi.org/10.1016/j.vaccine.2009.08.103</u>
- Waaler, H., Galtung, O., & Mordal, K. (1971). The risk of tuberculosis infection in Norway. *Bulletin of the International Union Against Tuberculosis and Lung Disease*, 45(45), 5–59.
- 821 Wardhana, D. E., Sultana, A., Mandang, V. V., & Jim, E. (2011). The efficacy of Bacillus Calmette-
- Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. *Acta Med Indones*, 43(3), 185–190.
- 824 Wen, M., & Gu, D. (2011). The Effects of Childhood, Adult, and Community Socioeconomic
- 825 Conditions on Health and Mortality among Older Adults in China. *Demography*, 48(1), 153–181.

- 826 Wilson, L. G. (1990). The historical decline of tuberculosis in Europe and America: Its causes and
- significance. *Journal of the History of Medicine and Allied Sciences*, 45(3), 366–396.
- 828 The World Bank (2022, February 1). Population, total Norway. Retrieved from
   829 <u>https://data.worldbank.org/indicator/SP.POP.TOTL?locations=NO</u>
- 830 World Health Organization. BCG vaccine. Retrieved from https://www.who.int/teams/health-product-
- 831 policy-and-standards/standards-and-specifications/vaccines-quality/bcg
- World Health Organization (2018). Bcg vaccine: Who position paper, February 2018 Recommendations. *Vaccine*, *36*(24), 3408–3410. <u>https://doi.org/10.1016/j.vaccine.2018.03.009</u>
- 834 World Health Organization (2021). Tuberculosis fact sheet. Retrieved from https://www.who.int/news-
- 835 <u>room/fact-sheets/detail/tuberculosis</u>
- 836 Zhao, L., Hessel, P., Simon Thomas, J., & Beckfield, J. (2021). Inequality in Place: Effects of Exposure
- to Neighborhood-Level Economic Inequality on Mortality. *Demography*, 58(6), 2041–2063.
  https://doi.org/10.1215/00703370-9463660
- Zwerling, A., Behr, M. A., Verma, A., Brewer, T. F., Menzies, D., & Pai, M. (2011). The BCG World
- 840 Atlas: A database of global BCG vaccination policies and practices. *PLoS Medicine*, 8(3), 1-8.
- 841 <u>https://doi.org/10.1371/journal.pmed.1001012</u>

## 843 **Table 1**: Regression Discontinuity Design estimation results for the effect of BCG vaccination

	То	tal	М	en	Woi	men
	below	above	below	above	below	above
	cut-off	cut-off	cut-off	cut-off	cut-off	cut-off
Sample size	323,169	383,905	339,754	343,064	103,683	139,722
Bandwidth	3.95	3.95	6.09	6.09	2.87	2.87

discontinuation on the cohort probability of survival from birth to age 30 in Sweden.

	Local average treatment effect (percentage points)				
Coefficient	0.00	0.05	-0.11		
95% CI	(-0.20 - 0.17)	(-0.17 - 0.25)	(-0.46 - 0.15)		
p-value	0.86	0.70	0.33		

Note: We estimated the Regression Discontinuity Design model by fitting a local linear trend including triangular
Kernel weights, a data-driven bandwidth selection, and a regularization term. The derivation of the optimal
bandwidth can result in a decimal. In line with Cattaneo et al. (2019), we used the floor of the decimal. The table
displays the local average treatment effect for the birth cohort of 1976 and confidence intervals resulting from
robust bias-corrected standard errors.

		Total	Men	Women
all	country*post	-0.06	-0.11	0.00
observations		(-0.11 - 0.00)	(-0.190.02)	(-0.07 - 0.07)
		0.04	0.02	0.91
observations	country*post	0.05	-0.05	0.06
within MSE		(-0.06 - 0.16)	(-0.18 - 0.07)	(-0.1 - 0.23)
optimal		0.39	0.40	0.44
bandwidth				

#### 851 **Table 2**: Pooled Difference in Difference estimates

852 Note: We pooled data from all pre-discontinuation and post-discontinuation years respectively.

853 Regression models include year dummies. The table displays 95% confidence intervals in parenthesis

and p-values in italic. The MSE optimal bandwidth was six for the full population, six for the male 854

855 population, and two for the female population. The cut-off year was 1975.

## 857 **Table 3**: Regression Kink Design estimation results

	Total		Men		Women	
	below	above	below	above	below	above
	cut-off	cut-off	cut-off	cut-off	cut-off	cut-off
Sample size	323,169	383,905	339,754	343,064	103,683	139,722
Bandwidth	3.56	3.56	5.01	5.01	2.83	2.83

Local average treatment effect (percentage points)

Coefficient	-0.06	-0.10	-0.01
95% CI	(-0.20 - 0.07)	(-0.24 - 0.00)	(-0.31 - 0.03)
p-value	0.35	0.05	0.78

858 Note: We estimated the Regression Kink Design model by fitting a local linear trend including triangular Kernel

859 weights, a data-driven bandwidth selection, and a regularization term. The derivation of the optimal bandwidth

860 can result in a decimal. In line with Cattaneo et al. (2019), we used the floor of the decimal. The table displays

the local average treatment effect for the birth cohort of 1976 and confidence intervals resulting from robust bias-

862 *corrected standard errors.* 





Note: We plotted the probability of survival to age 29, rather than 30, because data needed to construct

867 survival to age 30 were not available for France and Great Britain. The vertical line divides the birth cohorts

868 *into those born before the vaccine discontinuation (1975 and earlier) and those born after.* 

869



Figure 2: Cohort probability of survival from birth to age 30 in Sweden 871

872 Note: The vertical line divides the birth cohorts into those in or born before the year of the vaccine discontinuation

873 (1975 and earlier) and those born after.





875

MSE optimal bandwidth: +/- 3.95 years



#### of survival from birth to age 30 in Sweden 877

878 Note: Pink lines represent linear trends fitted separately for cohorts born before and after vaccine

879 discontinuation; blue lines are local linear trends fitted within the bandwidth and separately for cohorts born

880 before and after vaccine discontinuation; dashed lines represent the bandwidth determined by the data; purple

881 vertical line represents the year 1976, year of birth of the cohort from whom the local average treatment effect is

882 estimated.





#### Figure 4: Event study plot displaying multi-period difference in differences results 885

886 Note: Coefficients (with 95% confidence intervals) display the difference in the probability of survival between

887 cohorts born in the respective year in Sweden and Norway net the secular time trend and fixed countries

888 differences. The dashed vertical line marks the reference group, which is the cohort born in 1975.

- Supplementary Information for 890
- Does early childhood BCG vaccination improve survival into adulthood in a 891
- population with a low tuberculosis prevalence? Quasi-experimental evidence 892
- on non-specific effects from 39 Swedish birth cohorts 893



Figure S 1: Number of births (in thousands), years 1950 - 1988



902

threshold: 1976 MSE optimal bandwidth: +/- 6.09 years

Note: Pink lines represent linear trends fitted separately for cohorts born before and after vaccine
discontinuation; blue lines are local linear trends fitted within the bandwidth and separately for cohorts born
before and after vaccine discontinuation; dashed lines represent the bandwidth determined by the data; purple
vertical line represents the year 1976, year of birth of the cohort from whom the local average treatment effect
is estimated.

#### 909 Figure S 3: RDD: Non-specific effects of the BCG vaccine on long-term survival, female



911

912 Note: Pink lines represent linear trends fitted separately for cohorts born before and after vaccine 913 discontinuation; blue lines are local linear trends fitted within the bandwidth and separately for cohorts born 914 before and after vaccine discontinuation; dashed lines represent the bandwidth determined by the data; purple 915 vertical line represents the year 1976, year of birth of the cohort from whom the local average treatment effect

916 is estimated.

917

- 918 Figure S 4: Event study plot displaying multi-period difference in differences results, male
- 919 population





921 Note: coefficients (with 95% confidence intervals) display the difference in the probability of survival between
922 cohorts born in the respective year in Sweden and Norway net the secular time trend and fixed countries
923 differences. The dashed vertical line marks the reference group, which is the cohort born in 1975.

924

Figure S 5: Event study plot displaying multi-period difference in differences results, femalepopulation



Note: coefficients (with 95% confidence intervals) display the difference in the probability of survival between
 cohorts born in the respective year in Sweden and Norway net the secular time trend and fixed countries

- 930 differences. The dashed vertical line marks the reference group, which is the cohort born in 1975.
- 931







Note: The vertical line divides the birth cohorts into those born before the vaccine discontinuation (1975 and earlier) and those born after.

Figure S 7: Event study plot displaying multi-period difference in differences results; 



Note: coefficients (with 95% confidence intervals) display the difference in the probability of survival between cohorts born in the respective year in Sweden and Norway net the secular time trend and fixed countries differences. The dashed vertical line marks the reference group, which is the cohort born in 1974.

946 Figure S 8: Event study plot displaying multi-period difference in differences results, male



948

949 Note: coefficients (with 95% confidence intervals) display the difference in the probability of survival between
950 cohorts born in the respective year in Sweden and Norway net the secular time trend and fixed countries
951 differences. The dashed vertical line marks the reference group, which is the cohort born in 1974.

952

953

Figure S 9: Event study plot displaying multi-period difference in differences results, female
population; reference cohort: 1974



956

957 Note: coefficients (with 95% confidence intervals) display the difference in the probability of survival between 958 cohorts born in the respective year in Sweden and Norway net the secular time trend and fixed countries

959 differences. The dashed vertical line marks the reference group, which is the cohort born in 1974.

	Total	Men	Women
	coefficient (95% CI)	coefficient (95% CI)	coefficient (95% CI)
	p-value	p-value	p-value
1975	Ref.	Ref.	Ref.
	0.04 (-0.19 - 0.27)	0 (-0.35 - 0.36)	0.06 (-0.23 - 0.35)
1950	0.74	0.98	0.68
4054	-0.22 (-0.45 - 0.02)	-0.42 (-0.770.06)	-0.03 (-0.31 - 0.26)
1951	0.07	0.02	0.86
	-0.02 (-0.25 - 0.21)	-0.25 (-0.6 - 0.11)	0.2 (-0.08 - 0.49)
1952	0.85	0.17	0.16
	-0.17 (-0.4 - 0.06)	-0.29 (-0.65 - 0.06)	-0.05 (-0.33 - 0.24)
1953	0.14	0.11	0.76
	-0.21 (-0.45 - 0.02)	-0.5 (-0.850.14)	0.09 (-0.2 - 0.38)
1954	0.07	0.01	0.54
	-0.24 (-0.470.01)	-0.3 (-0.66 - 0.05)	-0.18 (-0.47 - 0.11)
1955	0.04	0.09	0.22
10 - 1	-0.05 (-0.28 - 0.18)	-0.02 (-0.37 - 0.34)	-0.07 (-0.36 - 0.22)
1956	0.68	0.93	0.63
	-0.27 (-0.50.04)	-0.41 (-0.770.06)	-0.12 (-0.41 - 0.17)
1957	0.02	0.02	0.41
40.50	0.02 (-0.21 - 0.25)	-0.12 (-0.47 - 0.24)	0.16 (-0.13 - 0.45)
1958	0.89	0.52	0.28
40.50	-0.19 (-0.42 - 0.04)	-0.17 (-0.53 - 0.18)	-0.22 (-0.51 - 0.07)
1959	0.11	0.35	0.14
40.60	-0.28 (-0.510.05)	-0.4 (-0.760.04)	-0.17 (-0.46 - 0.12)
1960	0.02	0.03	0.25
10/1	-0.07 (-0.3 - 0.16)	-0.12 (-0.48 - 0.23)	-0.02 (-0.31 - 0.27)
1961	0.57	0.50	0.88
10/0	-0.06 (-0.29 - 0.17)	-0.19 (-0.55 - 0.16)	0.06 (-0.22 - 0.35)
1962	0.59	0.29	0.67
10/2	-0.16 (-0.38 - 0.07)	-0.34 (-0.69 - 0.01)	0.06 (-0.23 - 0.34)
1963	0.18	0.06	0.70

# 960 Table S 1: Multi-period difference in differences estimation results

	Total	Men	Women
	coefficient (95% CI)	coefficient (95% CI)	coefficient (95% CI)
	p-value	p-value	p-value
10.64	0.01 (-0.21 - 0.24)	-0.11 (-0.46 - 0.24)	0.11 (-0.17 - 0.4)
1964	0.92	0.54	0.43
10/5	0.21 (-0.02 - 0.43)	0.17 (-0.18 - 0.52)	0.24 (-0.05 - 0.52)
1965	0.07	0.34	0.10
10//	-0.09 (-0.31 - 0.14)	-0.1 (-0.45 - 0.25)	-0.08 (-0.37 - 0.2)
1966	0.46	0.58	0.56
10/7	-0.14 (-0.36 - 0.09)	-0.16 (-0.51 - 0.19)	-0.11 (-0.39 - 0.17)
1967	0.24	0.37	0.44
10/0	-0.21 (-0.43 - 0.02)	-0.35 (-0.69 - 0)	-0.07 (-0.36 - 0.21)
1908	0.07	0.05	0.60
10/0	0.01 (-0.22 - 0.24)	-0.09 (-0.44 - 0.26)	0.11 (-0.18 - 0.39)
1969	0.95	0.61	0.45
1050	-0.09 (-0.32 - 0.13)	-0.03 (-0.38 - 0.32)	-0.18 (-0.46 - 0.11)
1970	0.42	0.86	0.23
1071	0.01 (-0.21 - 0.24)	0.01 (-0.34 - 0.36)	0.02 (-0.27 - 0.3)
19/1	0.91	0.95	0.91
1072	-0.12 (-0.34 - 0.11)	-0.25 (-0.6 - 0.1)	0.02 (-0.27 - 0.31)
1972	0.32	0.17	0.89
1073	-0.13 (-0.36 - 0.1)	-0.18 (-0.54 - 0.17)	-0.08 (-0.36 - 0.21)
1775	0.29	0.31	0.61
1074	-0.09 (-0.33 - 0.14)	-0.02 (-0.38 - 0.34)	-0.16 (-0.45 - 0.13)
1974	0.42	0.91	0.28
1076	-0.17 (-0.41 - 0.07)	-0.28 (-0.65 - 0.09)	-0.05 (-0.34 - 0.25)
1970	0.17	0.13	0.76
1977	-0.08 (-0.32 - 0.16)	-0.03 (-0.4 - 0.34)	-0.12 (-0.42 - 0.18)
1777	0.53	0.86	0.43
1978	-0.01 (-0.25 - 0.23)	-0.33 (-0.7 - 0.04)	0.32 (0.01 - 0.62)
1778	0.92	0.08	0.04
1979	0 (-0.24 - 0.24)	0.03 (-0.34 - 0.4)	-0.04 (-0.34 - 0.26)
1717	0.98	0.86	0.80
1080	-0.13 (-0.37 - 0.11)	-0.29 (-0.66 - 0.08)	0.03 (-0.27 - 0.33)
1700	0.30	0.13	0.83

	Total	Men	Women
	coefficient (95% CI)	coefficient (95% CI)	coefficient (95% CI)
	p-value	p-value	p-value
1091	-0.1 (-0.34 - 0.14)	-0.15 (-0.52 - 0.22)	-0.04 (-0.35 - 0.26)
1901	0.40	0.43	0.77
1092	-0.19 (-0.43 - 0.06)	-0.32 (-0.69 - 0.06)	-0.05 (-0.35 - 0.25)
1982	0.13	0.10	0.76
1092	-0.25 (-0.490.01)	-0.38 (-0.760.01)	-0.11 (-0.42 - 0.19)
1983	0.04	0.04	0.47
1094	-0.09 (-0.33 - 0.15)	-0.19 (-0.57 - 0.18)	0.02 (-0.28 - 0.32)
1904	0.46	0.31	0.89
1095	-0.24 (-0.48 - 0)	-0.35 (-0.72 - 0.02)	-0.13 (-0.43 - 0.17)
1985	0.05	0.07	0.39
1086	-0.34 (-0.580.1)	-0.56 (-0.930.19)	-0.12 (-0.42 - 0.18)
1900	0.00	0.00	0.43
1097	-0.31 (-0.540.07)	-0.65 (-1.010.28)	0.05 (-0.25 - 0.34)
1907	0.01	0.00	0.75
1088	-0.27 (-0.50.04)	-0.5 (-0.860.14)	-0.03 (-0.32 - 0.26)
1700	0.02	0.01	0.85

963 Note: coefficients are the difference in the probability of survival between cohorts born in the respective

964 year in Sweden and Norway net the secular time trend and fixed countries differences. The reference

965 group is the cohort born in 1975, the year of the vaccine discontinuation.

# 967

## 968 Table S 2: Regression Discontinuity Design estimation results, threshold year 1975

	Total		Men		Women	
	below	above	below	above	below	above
	cut-off	cut-off	cut-off	cut-off	cut-off	cut-off
Sample size	446,294	487,537	170,896	201,170	216,324	236,954
Bandwidth	4.03	4.03	3.37	3.37	4.79	4.79

Local average treatment effect (	percentage points)
	r ••• • ••••

Coefficient	0.06	0.02	0.09
95% CI	(-0.13 - 0.23)	(-0.31 - 0.33)	(-0.1 - 0.3)
p-value	0.59	0.97	0.33

969 Note: We estimated the Regression Discontinuity Design model by fitting a local linear trend including triangular

970 Kernel weights, a data-driven bandwidth selection, and a regularization term. The derivation of the optimal

971 bandwidth can result in a decimal. In line with Cattaneo et al. (2019), we used the floor of the decimal. The table

972 displays the local average treatment effect for the birth cohort of 1975 and confidence intervals resulting from

973 robust bias-corrected standard errors.

	Total	Men	Women
	coefficient (95% CI)	coefficient (95% CI)	coefficient (95% CI)
	p-value	p-value	p-value
1974	Ref.	Ref.	Ref.
1050	0.13 (-0.09 - 0.36)	0.02 (-0.32 - 0.37)	0.22 (-0.06 - 0.50)
1950	0.25	0.89	0.13
1051	-0.12 (-0.35 - 0.11)	-0.4 (-0.750.05)	0.13 (-0.15 - 0.42)
1951	0.30	0.03	0.35
1052	0.07 (-0.15 - 0.3)	-0.23 (-0.57 - 0.12)	0.36 (0.08 - 0.65)
1952	0.53	0.21	0.01
1053	-0.08 (-0.3 - 0.15)	-0.27 (-0.62 - 0.08)	0.11 (-0.17 - 0.4)
1955	0.50	0.13	0.43
1054	-0.12 (-0.35 - 0.11)	-0.48 (-0.830.13)	0.25 (-0.03 - 0.53)
1954	0.30	0.01	0.09
1055	-0.14 (-0.37 - 0.08)	-0.28 (-0.63 - 0.07)	-0.02 (-0.31 - 0.26)
1955	0.21	0.11	0.88
1056	0.05 (-0.18 - 0.27)	0.01 (-0.34 - 0.35)	0.09 (-0.19 - 0.37)
1950	0.69	0.98	0.53
1057	-0.17 (-0.4 - 0.06)	-0.39 (-0.740.04)	0.04 (-0.24 - 0.32)
1957	0.14	0.03	0.79
1059	0.11 (-0.12 - 0.34)	-0.1 (-0.45 - 0.25)	0.32 (0.03 - 0.6)
1338	0.34	0.59	0.03
1050	-0.1 (-0.32 - 0.13)	-0.15 (-0.5 - 0.2)	-0.06 (-0.34 - 0.22)
1959	0.41	0.40	0.68
1060	-0.19 (-0.42 - 0.04)	-0.38 (-0.730.03)	-0.01 (-0.3 - 0.28)
1900	0.10	0.04	0.94
1061	0.03 (-0.2 - 0.25)	-0.1 (-0.45 - 0.25)	0.14 (-0.15 - 0.42)
1901	0.81	0.57	0.34
1962	0.03 (-0.2 - 0.26)	-0.17 (-0.52 - 0.18)	0.22 (-0.06 - 0.51)
1702	0.79	0.34	0.12
1062	-0.06 (-0.29 - 0.16)	-0.32 (-0.67 - 0.03)	0.22 (-0.07 - 0.5)
1963	0.60	0.07	0.13

975	Table S 3: Multi-period	difference in differences	estimation results,	cut-off 1974
-----	-------------------------	---------------------------	---------------------	--------------

coefficient (95% CI)         coefficient (95% CI)         coefficient (95% CI)         coefficient (95% CI)           p-value         p-value         p-value         p-value           1964         0.11 (-0.12 - 0.33)         -0.09 (-0.43 - 0.26)         0.28 (0 - 0.55)           1965         0.3 (0.08 - 0.52)         0.19 (-0.15 - 0.53)         0.4 (0.12 - 0.67)           1966         0.01 (-0.21 - 0.23)         -0.08 (-0.42 - 0.26)         0.08 (-0.22 - 0.36)           1966         0.94         0.65         0.59           1967         -0.04 (-0.26 - 0.18)         -0.14 (-0.48 - 0.2)         0.05 (-0.23 - 0.33)           0.72         0.42         0.73           1968         -0.11 (-0.34 - 0.11)         -0.32 (-0.67 - 0.02)         0.09 (-0.19 - 0.36)           1969         0.1 (-0.12 - 0.33)         -0.07 (-0.42 - 0.27)         0.27 (-0.01 - 0.55)           1969         0.1 (-0.12 - 0.33)         -0.07 (-0.42 - 0.27)         0.27 (-0.01 - 0.55)           1970         0.10 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           1971         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           1971         0.35         0.86         0.22           1972         -0.02 (-0.25 - 0.2)         -0.23 (-0.57		Total	Men	Women	
p-value         p-value         p-value           1964         0.11 (-0.12 - 0.33)         -0.09 (-0.43 - 0.26)         0.28 (0 - 0.55)           0.35         0.62         0.05           1965         0.3 (0.08 - 0.52)         0.19 (-0.15 - 0.53)         0.4 (0.12 - 0.67)           0.01         0.28         0.01           1966         0.01 (-0.21 - 0.23)         -0.08 (-0.42 - 0.26)         0.08 (-0.2 - 0.36)           1966         0.94         0.65         0.59           1967         -0.04 (-0.26 - 0.18)         -0.14 (-0.48 - 0.2)         0.05 (-0.23 - 0.33)           0.72         0.42         0.73           1968         -0.11 (-0.14 - 0.11)         -0.32 (-0.67 - 0.02)         0.09 (-0.19 - 0.36)           0.37         0.69         0.06         0.55           1969         0.1 (-0.12 - 0.33)         -0.07 (-0.42 - 0.27)         0.27 (-0.01 - 0.55)           1969         0.1 (-0.12 - 0.33)         -0.07 (-0.42 - 0.27)         0.27 (-0.01 - 0.55)           1969         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           1970         1.00         0.95         0.91         0.27 (-0.03 - 0.27)           1971         0.01 (-0.25 - 0.2)         -0.02 (-0.25 - 0.2)         0.023 (-0.		coefficient (95% CI)	coefficient (95% CI)	coefficient (95% CI)	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		p-value	p-value	p-value	
1901         0.35         0.62         0.05           1965         0.3 (0.08 - 0.52)         0.19 (-0.15 - 0.53)         0.4 (0.12 - 0.67)           0.01         0.28         0.01           1966         0.01 (-0.21 - 0.23)         -0.08 (-0.42 - 0.26)         0.08 (-0.2 - 0.36)           1966         0.94         0.65         0.59           1967         -0.04 (-0.26 - 0.18)         -0.14 (-0.48 - 0.2)         0.05 (-0.23 - 0.33)           0.72         0.42         0.73           1968         -0.11 (-0.34 - 0.11)         -0.32 (-0.67 - 0.02)         0.09 (-0.19 - 0.36)           0.37         0.69         0.06         0.55           1969         0.1 (-0.12 - 0.33)         -0.07 (-0.42 - 0.27)         0.27 (-0.01 - 0.55)           1970         0 (-0.23 - 0.22)         -0.01 (-0.36 - 0.34)         -0.02 (-0.3 - 0.27)           1971         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           1971         0.11 (-0.12 - 0.33)         0.03 (-0.37 - 0.12)         0.18 (-0.1 - 0.46)           1972         -0.02 (-0.25 - 0.2)         -0.23 (-0.57 - 0.12)         0.18 (-0.1 - 0.46)           1971         0.11 (-0.12 - 0.33)         0.02 (-0.27 - 0.23)         0.21           1973         -0.03 (-0.	1064	0.11 (-0.12 - 0.33)	-0.09 (-0.43 - 0.26)	0.28 (0 - 0.55)	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	1704	0.35	0.62	0.05	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	1065	0.3 (0.08 - 0.52)	0.19 (-0.15 - 0.53)	0.4 (0.12 - 0.67)	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	1905	0.01	0.28	0.01	
1960         0.94         0.65         0.59           1967         -0.04 (-0.26 - 0.18)         -0.14 (-0.48 - 0.2)         0.05 (-0.23 - 0.33)           0.72         0.42         0.73           1968         -0.11 (-0.34 - 0.11)         -0.32 (-0.67 - 0.02)         0.09 (-0.19 - 0.36)           0.32         0.06         0.55           1969         0.1 (-0.12 - 0.33)         -0.07 (-0.42 - 0.27)         0.27 (-0.01 - 0.55)           0.90         0.37         0.69         0.06           1970         0 (-0.23 - 0.22)         -0.01 (-0.36 - 0.34)         -0.02 (-0.3 - 0.27)           1970         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           1971         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           1971         0.11 (-0.12 - 0.33)         0.03 (-0.57 - 0.12)         0.18 (-0.1 - 0.46)           1971         0.35         0.86         0.22           1972         -0.02 (-0.25 - 0.2)         -0.23 (-0.57 - 0.12)         0.18 (-0.1 - 0.46)           1973         0.79         0.36         0.56           1975         0.09 (-0.14 - 0.33)         0.02 (-0.34 - 0.38)         0.16 (-0.13 - 0.45)           1976         0.09 (-0.14 - 0.33)	1066	0.01 (-0.21 - 0.23)	-0.08 (-0.42 - 0.26)	0.08 (-0.2 - 0.36)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	1900	0.94	0.65	0.59	
1967         0.72         0.42         0.73           1968         -0.11 (-0.34 - 0.11)         -0.32 (-0.67 - 0.02)         0.09 (-0.19 - 0.36)           0.32         0.06         0.55           1969         0.1 (-0.12 - 0.33)         -0.07 (-0.42 - 0.27)         0.27 (-0.01 - 0.55)           0.9         0.37         0.69         0.06           1970         0 (-0.23 - 0.22)         -0.01 (-0.36 - 0.34)         -0.02 (-0.3 - 0.27)           1970         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           0.35         0.86         0.22         0.91           1971         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           0.35         0.86         0.22         0.21           1971         -0.02 (-0.25 - 0.2)         -0.23 (-0.57 - 0.12)         0.18 (-0.1 - 0.46)           0.85         0.20         0.21         0.91         0.28           1972         -0.03 (-0.26 - 0.2)         -0.16 (-0.51 - 0.19)         0.09 (-0.2 - 0.37)           0.79         0.36         0.56         0.56           1975         0.09 (-0.14 - 0.33)         0.02 (-0.34 - 0.38)         0.16 (-0.13 - 0.45)           1976         0.020 (-0.22 - 0.25)         -	10/7	-0.04 (-0.26 - 0.18)	-0.14 (-0.48 - 0.2)	0.05 (-0.23 - 0.33)	
1968         -0.11 (-0.34 - 0.11)         -0.32 (-0.67 - 0.02)         0.09 (-0.19 - 0.36)           1969         0.32         0.06         0.55           1969         0.1 (-0.12 - 0.33)         -0.07 (-0.42 - 0.27)         0.27 (-0.01 - 0.55)           1970         0.37         0.69         0.06           1970         0 (-0.23 - 0.22)         -0.01 (-0.36 - 0.34)         -0.02 (-0.3 - 0.27)           1970         0 (-0.23 - 0.22)         -0.01 (-0.36 - 0.34)         -0.02 (-0.3 - 0.27)           1971         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           0.35         0.86         0.22         0.91           1971         0.01 (-0.26 - 0.2)         -0.23 (-0.57 - 0.12)         0.18 (-0.1 - 0.46)           0.85         0.20         0.21         0.99         0.26           1972         -0.03 (-0.26 - 0.2)         -0.16 (-0.51 - 0.19)         0.09 (-0.2 - 0.37)           0.79         0.36         0.56         0.56           1975         0.09 (-0.14 - 0.33)         0.02 (-0.22 - 0.1)         0.11 (-0.18 - 0.41)           0.54         0.16         0.45         0.42         0.91         0.28           1976         0.02 (-0.22 - 0.25)         -0.01 (-0.38 - 0.35)         0.04 (-	1907	0.72	0.42	0.73	
1968         0.32         0.06         0.55           1969         0.1 (-0.12 - 0.33)         -0.07 (-0.42 - 0.27)         0.27 (-0.01 - 0.55)           0.37         0.69         0.06           1970         0 (-0.23 - 0.22)         -0.01 (-0.36 - 0.34)         -0.02 (-0.3 - 0.27)           1970         1.00         0.95         0.91           1971         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           0.35         0.86         0.22           1972         -0.02 (-0.25 - 0.2)         -0.23 (-0.57 - 0.12)         0.18 (-0.1 - 0.46)           0.85         0.20         0.21           1973         -0.03 (-0.26 - 0.2)         -0.16 (-0.51 - 0.19)         0.09 (-0.2 - 0.37)           0.79         0.36         0.56           1975         0.09 (-0.14 - 0.33)         0.02 (-0.34 - 0.38)         0.16 (-0.13 - 0.45)           0.42         0.91         0.28           1976         -0.07 (-0.31 - 0.16)         -0.26 (-0.62 - 0.1)         0.11 (-0.18 - 0.41)           0.54         0.16         0.45         0.42           1976         0.02 (-0.22 - 0.25)         -0.01 (-0.38 - 0.35)         0.04 (-0.26 - 0.34)           0.54         0.16         0.45	10/9	-0.11 (-0.34 - 0.11)	-0.32 (-0.67 - 0.02)	0.09 (-0.19 - 0.36)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	1908	0.32	0.06	0.55	
1969         0.37         0.69         0.06           1970         0 (-0.23 - 0.22)         -0.01 (-0.36 - 0.34)         -0.02 (-0.3 - 0.27)           1070         0.95         0.91           1971         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           0.35         0.86         0.22           1972         -0.02 (-0.25 - 0.2)         -0.23 (-0.57 - 0.12)         0.18 (-0.1 - 0.46)           0.85         0.20         0.21           1973         -0.03 (-0.26 - 0.2)         -0.16 (-0.51 - 0.19)         0.09 (-0.2 - 0.37)           0.79         0.36         0.56           1975         0.09 (-0.14 - 0.33)         0.02 (-0.34 - 0.38)         0.16 (-0.13 - 0.45)           0.42         0.91         0.28           1976         -0.07 (-0.31 - 0.16)         -0.26 (-0.62 - 0.1)         0.11 (-0.18 - 0.41)           0.54         0.16         0.45         0.42           1976         -0.07 (-0.31 - 0.16)         -0.26 (-0.62 - 0.1)         0.11 (-0.18 - 0.41)           0.54         0.16         0.45         0.45           1977         0.08 (-0.15 - 0.32)         -0.01 (-0.38 - 0.35)         0.04 (-0.26 - 0.34)           0.97         0.09 (-0.14 - 0.33)         0.	10/0	0.1 (-0.12 - 0.33)	-0.07 (-0.42 - 0.27)	0.27 (-0.01 - 0.55)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	1969	0.37	0.69	0.06	
1970         1.00         0.95         0.91           1971         0.11 (-0.12 - 0.33)         0.03 (-0.31 - 0.38)         0.18 (-0.1 - 0.46)           0.35         0.86         0.22           1972         -0.02 (-0.25 - 0.2)         -0.23 (-0.57 - 0.12)         0.18 (-0.1 - 0.46)           0.85         0.20         0.21           1973         -0.03 (-0.26 - 0.2)         -0.16 (-0.51 - 0.19)         0.09 (-0.2 - 0.37)           0.79         0.36         0.56           1975         0.09 (-0.14 - 0.33)         0.02 (-0.34 - 0.38)         0.16 (-0.13 - 0.45)           0.91         0.28         0.91         0.28           1976         0.09 (-0.14 - 0.33)         0.02 (-0.22 - 0.1)         0.11 (-0.18 - 0.41)           0.79         0.36         0.56         0.34           1976         0.02 (-0.22 - 0.25)         -0.01 (-0.38 - 0.35)         0.04 (-0.26 - 0.34)           1977         0.02 (-0.22 - 0.25)         -0.01 (-0.38 - 0.35)         0.04 (-0.26 - 0.34)           1977         0.02 (-0.22 - 0.25)         -0.01 (-0.38 - 0.35)         0.04 (-0.26 - 0.34)           1978         0.08 (-0.15 - 0.32)         -0.3 (-0.67 - 0.06)         0.48 (0.18 - 0.77)           0.89         0.95         0.79         0.42	1050	0 (-0.23 - 0.22)	-0.01 (-0.36 - 0.34)	-0.02 (-0.3 - 0.27)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	1970	1.00	0.95	0.91	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1071	0.11 (-0.12 - 0.33)	0.03 (-0.31 - 0.38)	0.18 (-0.1 - 0.46)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	19/1	0.35	0.86	0.22	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	1050	-0.02 (-0.25 - 0.2)	-0.23 (-0.57 - 0.12)	0.18 (-0.1 - 0.46)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	1972	0.85	0.20	0.21	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	1072	-0.03 (-0.26 - 0.2)	-0.16 (-0.51 - 0.19)	0.09 (-0.2 - 0.37)	
1975         0.09 (-0.14 - 0.33)         0.02 (-0.34 - 0.38)         0.16 (-0.13 - 0.45)         0.28           1976         0.42         0.91         0.28           1976         -0.07 (-0.31 - 0.16)         -0.26 (-0.62 - 0.1)         0.11 (-0.18 - 0.41)           0.54         0.16         0.45           1977         0.02 (-0.22 - 0.25)         -0.01 (-0.38 - 0.35)         0.04 (-0.26 - 0.34)           1977         0.02 (-0.22 - 0.25)         -0.01 (-0.38 - 0.35)         0.04 (-0.26 - 0.34)           1977         0.08 (-0.15 - 0.32)         -0.3 (-0.67 - 0.06)         0.48 (0.18 - 0.77)           1978         0.50         0.10         0.00           1979         0.09 (-0.14 - 0.33)         0.05 (-0.31 - 0.42)         0.12 (-0.17 - 0.42)           1979         0.45         0.77         0.42           1980         -0.03 (-0.27 - 0.2)         -0.27 (-0.63 - 0.1)         0.19 (-0.1 - 0.49)	1973	0.79	0.36	0.56	
1975         0.42         0.91         0.28           1976         -0.07 (-0.31 - 0.16)         -0.26 (-0.62 - 0.1)         0.11 (-0.18 - 0.41)           0.54         0.16         0.45           1977         0.02 (-0.22 - 0.25)         -0.01 (-0.38 - 0.35)         0.04 (-0.26 - 0.34)           1977         0.89         0.95         0.79           1978         0.08 (-0.15 - 0.32)         -0.3 (-0.67 - 0.06)         0.48 (0.18 - 0.77)           1978         0.09 (-0.14 - 0.33)         0.05 (-0.31 - 0.42)         0.12 (-0.17 - 0.42)           1979         0.45         0.77         0.42           1980         -0.03 (-0.27 - 0.2)         -0.27 (-0.63 - 0.1)         0.19 (-0.1 - 0.49)           0.78         0.15         0.20         0.20	1075	0.09 (-0.14 - 0.33)	0.02 (-0.34 - 0.38)	0.16 (-0.13 - 0.45)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	1975	0.42	0.91	0.28	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	107/	-0.07 (-0.31 - 0.16)	-0.26 (-0.62 - 0.1)	0.11 (-0.18 - 0.41)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	1976	0.54	0.16	0.45	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	1077	0.02 (-0.22 - 0.25)	-0.01 (-0.38 - 0.35)	0.04 (-0.26 - 0.34)	
1978         0.08 (-0.15 - 0.32)         -0.3 (-0.67 - 0.06)         0.48 (0.18 - 0.77)         0.00           0.50         0.10         0.00           1979         0.09 (-0.14 - 0.33)         0.05 (-0.31 - 0.42)         0.12 (-0.17 - 0.42)           0.45         0.77         0.42           1980         -0.03 (-0.27 - 0.2)         -0.27 (-0.63 - 0.1)         0.19 (-0.1 - 0.49)           0.78         0.15         0.20	19//	0.89	0.95	0.79	
1978         0.50         0.10         0.00           1979         0.09 (-0.14 - 0.33)         0.05 (-0.31 - 0.42)         0.12 (-0.17 - 0.42)           0.45         0.77         0.42           1980         -0.03 (-0.27 - 0.2)         -0.27 (-0.63 - 0.1)         0.19 (-0.1 - 0.49)           0.78         0.15         0.20	1070	0.08 (-0.15 - 0.32)	-0.3 (-0.67 - 0.06)	0.48 (0.18 - 0.77)	
1979         0.09 (-0.14 - 0.33)         0.05 (-0.31 - 0.42)         0.12 (-0.17 - 0.42)           0.45         0.77         0.42           1980         -0.03 (-0.27 - 0.2)         -0.27 (-0.63 - 0.1)         0.19 (-0.1 - 0.49)           0.78         0.15         0.20	1978	0.50	0.10	0.00	
1979         0.45         0.77         0.42           1980         -0.03 (-0.27 - 0.2)         -0.27 (-0.63 - 0.1)         0.19 (-0.1 - 0.49)           0.78         0.15         0.20	1070	0.09 (-0.14 - 0.33)	0.05 (-0.31 - 0.42)	0.12 (-0.17 - 0.42)	
1980-0.03 (-0.27 - 0.2) 0.78-0.27 (-0.63 - 0.1) 0.19 (-0.1 - 0.49) 0.20	1979	0.45	0.77	0.42	
0.78 0.15 0.20	1000	-0.03 (-0.27 - 0.2)	-0.27 (-0.63 - 0.1)	0.19 (-0.1 - 0.49)	
	1980	0.78	0.15	0.20	

	Total	Men	Women	
	coefficient (95% CI)	coefficient (95% CI)	coefficient (95% CI)	
	p-value	p-value	p-value	
1091	-0.01 (-0.25 - 0.23)	-0.13 (-0.5 - 0.24)	0.12 (-0.18 - 0.41)	
1701	0.94	0.49	0.44	
1083	-0.09 (-0.33 - 0.15)	-0.29 (-0.66 - 0.07)	0.11 (-0.18 - 0.41)	
1982	0.45	0.11	0.46	
1093	-0.15 (-0.39 - 0.08)	-0.36 (-0.73 - 0.01)	0.05 (-0.25 - 0.35)	
1903	0.21	0.05	0.75	
1094	0 (-0.23 - 0.24)	-0.17 (-0.54 - 0.2)	0.18 (-0.12 - 0.48)	
1704	0.98	0.36	0.23	
1085	-0.15 (-0.38 - 0.09)	-0.33 (-0.69 - 0.04)	0.03 (-0.27 - 0.32)	
1903	0.23	0.08	0.85	
1086	-0.25 (-0.480.01)	-0.54 (-0.90.18)	0.04 (-0.25 - 0.33)	
1700	0.04	0.00	0.79	
1087	-0.21 (-0.45 - 0.02)	-0.63 (-0.990.27)	0.21 (-0.08 - 0.5)	
190/	0.07	0.00	0.16	
1088	-0.18 (-0.4 - 0.05)	-0.48 (-0.830.13)	0.13 (-0.16 - 0.42)	
1988	0.13	0.01	0.37	

977 Note: coefficients are the difference in the probability of survival between cohorts born in the respective

978 year in Sweden and Norway net the secular time trend and fixed countries differences. As a robustness

979 check, we defined the reference group to be the cohort born in 1974, the year before the vaccine

980 discontinuation.

#### 981 Table S 4: Pooled Difference in Difference estimates, cut-off 1974

	Total	Male	Female
country*post	-0.05	-0.08	-0.02
	(-0.11 - 0.00)	(-0.16 - 0.01)	(-0.09 - 0.05)
	0.05	0.07	0.56

982 Note: We pooled data from all pre-discontinuation and post-discontinuation years respectively.

983 Regression models include year dummies. The table displays 95% confidence intervals in parenthesis 984 and p-values in italic. The cut-off year was 1974.

985

# 987 Table S 5: Regression Discontinuity Design estimation results with increasing bandwidth

		Total popula	ation (MSE: +/-	- 3.95 years)			
	MSE optima	al bandwidth	MSE optima	al bandwidth	MSE optima	al bandwidth	
	+ 1 year		+ 2 year		+ 3 year		
	below	above	below	above	below	above	
	cut-off	cut-off	cut-off	cut-off	cut-off	cut-off	
Sample size	435,442	480,969	549,926	575,034	660,076	667,782	
Bandwidth	4.95	4.95	5.95	5.95	6.95	6.95	
	Local average treatment effect (percentage points)						
Coefficient	0.02		0.04		0.04		
95% CI	(-0.30 - 0.19)		(-0.23	(-0.23 - 0.16)		(-0.18 - 0.17)	
p-value	0.66		0.73		0.96		

988

Male population (MSE: +/- 7.09 years)							
	MSE optima	MSE optimal bandwidth		MSE optimal bandwidth		MSE optimal bandwidth	
	+ 1	year	+ 2	+ 2 year		+ 3 year	
	below	above	below	above	below	above	
	cut-off	cut-off	cut-off	cut-off	cut-off	cut-off	
Sample size	395,382	390,377	453,503	438,717	516,031	489,465	
Bandwidth	7.09	7.09	8.09	8.09	9.09	9.09	
Local average treatment effect (percentage points)							
Coefficient	0.04		0.05		0.04		
95% CI	(-0.22 - 0.29)		(-0.20 - 0.26)		(-0.17 - 0.25)		
p-value	0.79		0.80		0.70		

Female population (MSE: +/- 3.87 years)							
	MSE optima	l bandwidth	MSE optima	MSE optimal bandwidth		MSE optimal bandwidth	
	+ 1 year		+ 2	+ 2 year		+ 3 year	
	below	above	below	above	below	above	
	cut-off	cut-off	cut-off	cut-off	cut-off	cut-off	
Sample size	156935	186564	211304	233768	266714	279702	
Bandwidth	3.87	3.87	4.87	4.87	5.87	5.87	
	Local average treatment effect (percentage points)						
Coefficient	-0.05		0.00		0.03		
95% CI	(-0.65 - 0.28)		(-0.49 - 0.14)		(-0.34 - 0.16)		
p-value	0.44		0.27		0.47		

990 Note: We estimated the Regression Discontinuity Design model by fitting a local linear trend including triangular

991 Kernel weights, a data-driven bandwidth selection, and a regularization term. The derivation of the optimal

992 bandwidth can result in a decimal. In line with Cattaneo et al. (2019), we used the floor of the decimal. We

993 increased the MSE optimal bandwidth by one, two, and three years respectively as a robustness check. The table

994 displays the local average treatment effect for the birth cohort of 1976 and confidence intervals resulting from

995 robust bias-corrected standard errors.

996